NAYA Biosciences (NAYA) 10-K 30 Mar 21 2020 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2020	Mar. 15, 2021	Jun. 30, 2020
Document Information Line Items
Entity Registrant Name	INVO Bioscience, Inc.,
Document Type	10-K
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		10,420,380
Entity Public Float			$ 19,556,356
Amendment Flag	false
Entity Central Index Key	0001417926
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Dec. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Interactive Data Current	Yes

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Current assets
Cash	$ 10,097,760	$ 1,238,585
Accounts receivable net	21,699	7,558
Inventory, net	265,372	101,387
Prepaid expenses and other current assets	157,700	195,910
Total current assets	10,542,531	1,543,440
Property and equipment, net	132,206	93,055
Capitalized patents, net	5,427	7,234
Lease right of use	79,319	101,883
Trademarks	89,536	49,867
Other assets	240	0
Investment in joint ventures	98,084	0
Total other assets	272,606	158,984
Total assets	10,947,343	1,795,479
Current liabilities
Accounts payable and accrued liabilities, including related parties	328,927	371,530
Accrued compensation	527,326	393,017
Deferred revenue	714,286	714,286
Current portion of lease liability	22,707	21,365
Note payable – Payroll Protection Program	157,620	0
Convertible notes, net	536,063	0
Income taxes payable	1,062	912
Total current liabilities	2,287,991	1,501,110
Lease liability, net of current portion	58,634	81,494
Deferred revenue, net of current portion	2,857,143	3,571,429
Convertible notes, net	0	325,784
Convertible notes – related party, net	0	28,824
Deferred tax liability	469	433
Total liabilities	5,204,237	5,509,074
Common Stock, $.0001 par value; 125,000,000 shares authorized; 9,639,268 and 4,884,879 issued and outstanding as of December 31, 2020 and December 31, 2019, respectively	964	489
Additional paid-in capital	37,978,224	20,174,682
Accumulated deficit	(32,236,082)	(23,888,766)
Total stockholders’ equity (deficiency)	5,743,106	(3,713,595)
Total liabilities and stockholders' equity (deficiency)	$ 10,947,343	$ 1,795,479

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parentheticals) - $ / shares	Dec. 31, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Common Stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common Stock, shares authorized	125,000,000	125,000,000
Common Stock, shares issued	9,639,268	4,884,879
Common Stock, shares outstanding	9,639,268	4,884,879

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Revenue:
Revenue	$ 1,037,286	$ 1,480,213
Cost of goods sold:
Production costs	79,035	133,664
Depreciation	9,725	6,006
Total Cost of goods sold	88,760	139,670
Gross margin	948,526	1,340,543
Research and development expenses	398,426	0
Selling, general and administrative expenses	6,065,066	3,128,635
Total operating expenses	6,463,492	3,128,635
Loss from operations	(5,514,966)	(1,788,092)
Other income (expense):
Interest income	4,190	8,627
Interest expense	(2,836,504)	(387,646)
Total other ( income) expenses	(2,832,314)	(379,019)
Loss before income taxes	(8,347,280)	(2,167,111)
Provision for income taxes	(36)	(433)
Net loss	$ (8,347,316)	$ (2,167,544)
Net loss per common share:
Basic net loss per weighted average shares of common stock (in Dollars per share)	$ (1.52)	$ (0.45)
Diluted net loss per weighted average shares of common stock (in Dollars per share)	$ (1.52)	$ (0.45)
Weighted average number of common shares outstanding:
Basic weighted average number of shares of common stock (in Shares)	5,489,738	4,854,878
Diluted weighted average number of shares of common stock (in Shares)	5,489,738	4,854,878
Product Revenue [Member]
Revenue:
Revenue	$ 323,000	$ 765,927
License [Member]
Revenue:
Revenue	$ 714,286	$ 714,286

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY DEFICIENCY - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2018	$ 482	$ 18,996,517	$ (21,721,222)	$ (2,724,223)
Balance (in Shares) at Dec. 31, 2018	4,821,641
Common stock issued to directors and employees	$ 1	17,749		17,750
Common stock issued to directors and employees (in Shares)	12,500
Common stock issued for services	$ 1	45,999		46,600
Common stock issued for services (in Shares)	4,062
Conversion of Note payable	$ 4	238,719		238,723
Conversion of Note payable (in Shares)	37,301
Common stock issues for settlement	$ 1	93,749		93,750
Common stock issues for settlement (in Shares)	9,375
Stock options issued to directors and employees as compensation		69,787		69,787
Settlement of accrued compensation		712,162		712,162
Net loss			(2,167,544)	(2,167,544)
Balance at Dec. 31, 2019	$ 489	20,174,682	(23,888,766)	$ (3,713,595)
Balance (in Shares) at Dec. 31, 2019	4,884,879			4,884,879
Common stock sold for cash, net of offering costs	$ 416	11,474,636		$ 11,475,052
Common stock sold for cash, net of offering costs (in Shares)	4,153,750
Common stock issued to directors and employees	$ 11	465,129		465,140
Common stock issued to directors and employees (in Shares)	112,056
Common stock issued for services	$ 3	150,859		150,862
Common stock issued for services (in Shares)	34,751
Conversion of Note payable	$ 45	1,451,779		1,451,824
Conversion of Note payable (in Shares)	453,699
Discount on convertible notes		3,120,150		3,120,150
Stock options issued to directors and employees as compensation		1,140,989		1,140,989
Rounding shares as the result of reverse stock split (in Shares)	133
Net loss			(8,347,316)	(8,347,316)
Balance at Dec. 31, 2020	$ 964	$ 37,978,224	$ (32,236,082)	$ 5,743,106
Balance (in Shares) at Dec. 31, 2020	9,639,268			9,639,268

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities:
Net loss	$ (8,347,316)	$ (2,167,544)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Non-cash stock compensation issued for services	150,862	46,000
Non-cash stock compensation issued to directors and employees	465,140	17,750
Fair value of stock options issued to employees	1,140,989	69,787
Loss on settlement of debt	0	93,750
Amortization of discount on notes payable	2,494,236	337,413
Debt conversion expense	131,984	0
Amortization of leasehold right of use asset	22,564	14,558
Depreciation and amortization	11,917	10,788
Changes in assets and liabilities:
Accounts receivable	(14,141)	218,341
Inventories	(163,985)	(57,874)
Prepaid expenses and other current assets	38,210	53,544
Deferred revenue	(714,286)	4,266,820
Accounts payable and accrued expenses	(42,603)	(200,298)
Leasehold liability	(21,518)	(13,582)
Accrued interest - related party	(61,696)	89,792
Accrued compensation	134,309	(1,410,077)
Income taxes payable	150	912
Deferred tax liabilities	36	433
Net cash provided by (used in) operating activities	(4,775,148)	1,370,513
Cash flows from investing activities:
Payments to acquire property, plant and equipment	(49,261)	(64,839)
Payments to acquire property, plant and equipment	(39,669)	(49,867)
Other assets	(240)	0
Investment in joint ventures	(98,084)	0
Net cash (used) in investing activities	(187,254)	(114,706)
Cash flows from financing activities:
Proceeds from the sale of common stock, net of offering costs	11,475,052	0
Proceeds from sale of convertible notes payable, net of issuance costs	2,998,905	0
Proceeds from convertible notes payable	157,620	0
Principal payments on note payable - related parties	(40,000)	(97,743)
Cash paid for notes payable	(770,000)	(131,722)
Net cash (used in) provided by financing activities	13,821,577	(229,465)
Increase (decrease) in cash and cash equivalents	8,859,175	1,026,342
Cash and cash equivalents at beginning of period	1,238,585	212,243
Cash and cash equivalents at end of period	10,097,760	1,238,585
Cash paid during the period for:
Interest	253,392	84,043
Taxes	1,062	912
Common stock issued for prepaid services	0	0
Leasehold right of use asset and leasehold liability upon adoption of ASU 2016-02, lease (Topic 842)	0	116,441
Common stock issued upon note payable and accrued interest conversion	1,451,824	238,723
Beneficial conversion feature on convertible notes	2,062,586	0
Settlement of accrued compensation	0	712,162
Fair value of options issued for debt	524,452	0
Fair value of warrants issued with debt	524,452	0
Fair value of warrants issued to service providers	$ 8,660	$ 0

ORGANIZATION AND SUMMARY OF SIG

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	NOTE 1 ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (A) General INVO Bioscience (“INVO” or the “Company”) is a medical device company focused on the Assisted Reproductive Technology (“ART”) marketplace. The primary focus is the manufacture and sale of the INVOcell device and the INVO technology to provide an alternative infertility treatment for couples. The Company’s patented device, the INVOcell, is the first Intravaginal Culture (“IVC”) system in the world used for the natural in vivo in vivo In both current utilization of the INVOcell and in clinical studies, the INVO Procedure has proven to have equivalent pregnancy success and live birth rates as the traditional assisted reproductive technique, IVF. Additionally, we believe there are emotional benefits of the mother’s participation in the fertilization and early embryo development by vaginal incubation compared to that of conventional IVF treatment. INVOcell also offers to patients a more personalized way to achieve pregnancy. (B) Basis of Presentation (Share Exchange and Corporate Structure) The accompanying consolidated financial statements present on a consolidated basis the accounts of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. Medesole JV Agreement On January 16, 2020, the Company announced a joint venture agreement for the Indian market. Under terms of the agreement, INVO and our partner, Medesole Healthcare and Trading Pvt Ltd (“Medesole”), will each own 50% of the joint venture. The Company will provide the device, training and general technology support to the joint venture, while Medesole will be responsible for the operations of INVO clinics in India. Both partners will equally invest in start-up and capital expenditures and share in the revenue and profits of the joint venture. The business model allows INVO to benefit not only from the sale of the device, but from the delivery of the entire solution. The current joint venture arrangements are in the developmental stage and therefore only the initial startup costs are included in the financial statement for the year ended December 31, 2020. Mexico JV Agreement Effective September 24, 2020, INVO Centers, LLC, entered into a Pre-Incorporation and Shareholders Agreement with Francisco Arredondo, MD PLLC (“Arredondo”) and Security Health LLC, a Texas limited liability company (“Ramirez”, and together with INVO and Arredondo, the “Shareholders”) under which the Shareholders will commercialize the INVO Procedure and offer related medical treatments in Mexico. Each party will own one-third of the Mexican incorporated company, Positib Fertility, S.A. de C.V. (the “Mexico Company”). The Mexico Company will acquire the INVOcell product at cost plus any incurred shipping, customs and related fees. The Mexico Company will operate in Monterrey Nuevo Leon, Mexico and any other cities and places in Mexico as approved by the Mexico Company’s board of directors and Shareholders. In addition, the Shareholders agreed that the Mexico Company will be the Company’s exclusive distributor in Mexico. The Shareholders also agreed not to compete directly or indirectly with the Mexico Company in Mexico. For the year ended December 31, 2020 the Company has invested $51,670 in this joint venture. This joint venture arrangements are in the developmental stage and therefore only the initial startup costs are included in the financial statement for the year ended December 31, 2020. North Macedonia JV Agreement On November 23, 2020, the Company entered into a joint venture agreement with Ginekaliks Dooel (“Ginekaliks”), a limited liability company incorporated in the Republic of North Macedonia, to establish an exclusive joint venture to (i) commercialize, introduce, promote and market technologies related to the INVOcell and INVO Procedure in North Macedonia, (ii) establish a private healthcare institution to offer the INVO Procedure. The joint venture will be co-managed and owned 50% by each of INVO and Ginekaliks. For the year ended December 31, 2020 the Company has invested $2,597 in this joint venture. This joint venture arrangements are in the developmental stage and therefore only the initial startup costs are included in the financial statement for the year ended December 31, 2020. Malaysia JV Agreement On November 23, 2020, the Company entered into a separate joint venture agreement with SNS Murni SDN BHD (“SNS Murni”), a company incorporated in Malaysia, to establish an exclusive joint venture in Malaysia to (i) introduce, promote and market our technologies related to the INVOcell and INVO Procedure in dedicated government-owned fertility clinics in Malaysia, and (ii) establish INVO Clinics in Malaysia. The joint venture will be co-managed and owned 50% by each of INVO Bioscience and SNS Murni. For the year ended December 31, 2020 the Company has invested $7,348 in this joint venture. This joint venture arrangements are in the developmental stage and therefore only the initial startup costs are included in the financial statement for the year ended December 31, 2020. (C) Use of Estimates In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates. (D) Cash and Cash Equivalents For financial statement presentation purposes, the Company considers time deposits, certificates of deposit and all highly liquid investments with original maturities of three months or less to be cash and cash equivalents. At times, cash and cash equivalents balances exceed amounts insured by the Federal Deposit Insurance Corporation. (E) Inventory Inventories consist of raw materials, work in process and finished products and are stated at the lower of cost or market; using the first-in, first-out (FIFO) method as a cost flow convention. (F) Property and Equipment The Company records property and equipment at cost. Property and equipment is depreciated using the straight-line method over the estimated economic lives of the assets, which are from 3 to 10 years. The Company capitalizes the expenditures for major renewals and improvements that extend the useful lives of property and equipment. Expenditures for maintenance and repairs are charged to expense as incurred. The Company reviews the carrying value of long-lived assets for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets is measured by a comparison of its carrying amount to the undiscounted cash flows that the asset or asset group is expected to generate. If such assets are considered impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the property, if any, exceeds its fair market value. (G) Stock Based Compensation The Company accounts for stock-based compensation under the provisions of Accounting Standards Codification subtopic 718-10, Compensation (“ASC 718-10”). This statement requires the Company to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. That cost is recognized over the period in which the employee is required to provide service or based on performance goals in exchange for the award, which is usually the vesting period. ( H) Loss Per Share Basic loss per share calculations are computed by dividing income (loss) available to common shareholders by the weighted-average number of common shares outstanding. Diluted earnings per share are computed similar to basic earnings per share except that the denominator is increased to include securities or other contracts to issue common stock that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. The Company’s diluted loss per share is the same as the basic loss per share for the years ended December 31, 2020 and 2019, as the inclusion of any potential shares would have had an anti-dilutive effect due to the Company generating a loss. Years Ended December 31, 2020 2019 Loss to common shareholders (Numerator) $ (8,347,316 ) $ (2,167,544 ) Basic and diluted weighted-average number of common shares outstanding (Denominator) 5,489,738 4,854,878 The Company has excluded the following dilutive securities from the calculation of fully diluted shares outstanding because the result would have been anti-dilutive: Years Ended December 31, 2020 2019 Effect of dilutive common stock equivalents: Options 594,114 260,018 Convertible notes and interest 536,302 85,324 Warrants 613,996 - Total 1,744,412 345,342 ( I) Fair Value of Financial Instruments ASC 825-10-50, “Disclosures about Fair Value of Financial Instruments,” requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and borrowings, as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. Effective January 1, 2008, the Company adopted ASC 820-10, “Fair Value Measurements”, which provides a framework for measuring fair value under GAAP. ASC 820-10 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820-10 requires that valuation techniques maximize the use of observable inputs and minimize the use of unobservable inputs. (J) Income Taxes The Company is subject to income taxes in the United States and its domestic tax liabilities are subject to the allocation of expenses in multiple state jurisdictions. The Company uses the asset and liability method to account for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The recoverability of deferred tax assets is evaluated by assessing the adequacy of future expected taxable income from all sources, including taxable income in prior carryback years, reversal of taxable temporary differences, forecasted operating earnings and available tax planning strategies. To the extent the Company does not consider it more-likely-than-not that a deferred tax asset will be recovered, a valuation allowance is established. (K) Business Segments The Company operates in one segment and therefore segment information is not presented. (L) Concentration of Credit Risk Cash includes amounts deposited in financial institutions in excess of insurable Federal Deposit Insurance Corporation (“FDIC”) limits. As of December 31, 2020, the Company had cash balances in excess of FDIC limits. (M) Revenue Recognition The Company recognizes revenue on arrangements in accordance with ASC 606, Revenue from Contracts with Customers (“ASC 606”). The core principle of ASC 606 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services ASC 606 requires companies to assess their contracts to determine the timing and amount of revenue to recognize under the new revenue standard. The model has a five-step approach: 1. Identify the contract with the customer. 2. Identify the performance obligations in the contract. 3. Determine the total transaction price. 4. Allocate the total transaction price to each performance obligation in the contract. 5. Recognize as revenue when (or as) each performance obligation is satisfied. Revenues for products, including: INVOcell®, INVO TM Retention System, and INVO Microscope Holding Block are typically recognized at the time the product is shipped, at which time the title passes to the customer, and there are no further performance obligations. On November 12, 2018, we entered into a U.S. Distribution Agreement (the “Distribution Agreement”) with Ferring International Center S.A. (“Ferring”), which closed on January 14, 2019. At the closing, we received a $5,000,000 license payment upfront from Ferring. Pursuant to the Distribution Agreement, among other things, we granted Ferring an exclusive license in the United States market only, with rights to sublicense under patents related to our proprietary intravaginal culture device (INVOcell™), together with the retention device and any other applicable accessories (collectively, the “Licensed Product”) to market, promote, distribute and sell the Licensed Product with respect to all therapeutic, prophylactic and diagnostic uses of medical devices or pharmaceutical products involving reproductive technology (including infertility treatment) in humans (the “Field”). Ferring is responsible, at its own cost, for all commercialization activities for the Licensed Product in the U.S. market. We retained a limited exception to the exclusive license granted to Ferring allowing us, subject to certain restrictions, to establish up to five clinics that will commercialize INVO cycles in the U.S. This agreement was amended on March 2, 2021 to provide for added flexibility by increasing the number of INVO company-owned clinics initially allowable under the agreement and removing certain geographical requirements. Ferring is obligated to make a second payment to us of $3,000,000 upon procurement of a five (5) day label enhancement from the FDA for the current incubation period for the Licensed Product at least three (3) years prior to the expiration of the term of the license for the Licensed Product and provided further that Ferring has not previously exercised its right to terminate the Distribution Agreement for convenience. In addition, under the terms of a separate Supply Agreement, Ferring is obligated to pay us a specified supply price for each Licensed Product purchased by Ferring for distribution. The Distribution Agreement has an initial term expiring on December 31, 2025 and at the end of the initial term it may be terminated by us if Ferring fails to generate specified minimum revenues to us from the sale of the Licensed Product during the final two years of the initial term. Provided that no such termination occurs at the end of the initial term, thereafter the term of the Distribution Agreement shall automatically be renewed for successive three (3) years terms unless terminated by mutual consent. We retain all commercialization rights for the Licensed Product outside of the United States. The Ferring license was deemed to be a functional license that provide customers with a “right to access” to our intellectual property during the subscription period and accordingly, under ASC 606-10-55-60 revenue is recognized over a period of time, which is generally the subscription period. The initial upfront payment of $5,000,000 which was received upon the signing of the agreement is being recognized to income over the 7 year term. (N) Long- Lived Assets Long-lived assets and certain identifiable assets related to those assets are periodically reviewed for impairment whenever circumstances and situations change such that there is an indication that the carrying amounts may not be recoverable. If the non-discounted future cash flows of the enterprise are less than their carrying amount, their carrying amounts are reduced to the fair value and an impairment loss recognized. There was no impairment recorded during the years ended December 31, 2020 and 2019. (O) Recent Accounting Pronouncements In February 2016, FASB issued ASU 2016-02, Leases (“ASU 2016-02”). The new standard establishes a right-of-use (“ROU”) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company adopted the standard effective January 1, 2019. The standard allows a number of optional practical expedients to use for transition. The Company chose the certain practical expedients allowed under the transition guidance which permitted the Company to not to reassess any existing or expired contracts to determine if they contain embedded leases, to not to reassess our lease classification on existing leases, to account for lease and non-lease components as a single lease component for equipment leases, and whether initial direct costs previously capitalized would qualify for capitalization under FASB ASC 842. The new standard also provides practical expedients and recognition exemptions for an entity's ongoing accounting policy elections. The Company has elected the short-term lease recognition for all leases that qualify, which means that we do not recognize a ROU asset and lease liability for any lease with a term of twelve months or less. The most significant impact of adopting the standard was the recognition of ROU assets and lease liabilities for operating leases on the Company's consolidated balance sheet but it did not have an impact on the Company's consolidated statements of operations or consolidated statements of cash flows. The Company did not have a cumulative effect on adoption prior to January 1, 2019. The Company adopted Accounting Standards Update No. 2016-02: Leases, or ASU 2016-02, effective January 1, 2019. ASC 842 superseded previously existing guidance on accounting for leases and generally requires all leases to be recognized in the statement of financial position. The adoption of ASC 842 had no impact on the Company’s consolidated statement of operations and consolidated statement of cash flows. The Company adopted ASC 842 on a modified retrospective approach at the effective date and, therefore, did not revise comparative period information or disclosure. In addition, the Company elected the package of practical expedients permitted under ASC 842. In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. This standard is intended to simplify the accounting and disclosure requirements for income taxes by eliminating various exceptions in accounting for income taxes as well as clarifying and amending existing guidance to improve consistency in application of ASC 740. The provisions of ASU 2019-12 are effective for fiscal years beginning after December 15, 2021, with early adoption permitted. The Company is currently evaluating the impact that ASU 2019-12 will have on its consolidated financial statements. In July 2017, FASB issued ASU 2017-11 (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception (“ASU 2017-11”). The new standard simplifies the accounting for certain financial instruments with down round features. Part I of ASU 2017-11 changes the classification analysis of certain equity-linked financial instruments, such as warrants and embedded conversion features, such that a down round feature is disregarded when assessing whether the instrument is indexed to an entity’s own stock under Subtopic 815-40, Contracts in Entity’s Own Equity. As a result, a down round feature, by itself, no longer requires an instrument to be re-measured at fair value through earnings each period, although all other aspects of the indexation guidance under Subtopic 815-40 continue to apply. Part II of ASU 2017-11 re-characterizes the indefinite deferral of certain provisions of Topic 480, Distinguishing Liabilities from Equity, (currently presented as pending content in the Codification) as a scope exception. No change in practice is expected as a result of these amendments. The new standard is effective for fiscal years beginning after December 15, 2018, early adoption is permitted. The amendments in Part II have no accounting impact and therefore do not have an associated effective date. The Company decided to early adopt this ASU 2017-11 and applied it to the convertible notes it issued during the quarter which are reflected in this Form 10-K. Management was not aware of any accounting issued, but not yet effective accounting standards, if currently adopted would have material effect on the consolidated financial statements. (P) Reverse Stock Splits On May 26, 2020, the Company effected a 1-for-20 reverse stock split of its common stock. All shares, options and warrants throughout these consolidated financial statements have been retroactively restated to reflect the reverse split. On November 9, 2020, the Company effected a 5-for-8 reverse stock split of its common stock. All shares, options and warrants throughout these consolidated financial statements have been retroactively restated to reflect the reverse split.

LIQUIDITY

LIQUIDITY	12 Months Ended
	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Substantial Doubt about Going Concern [Text Block]	NOTE 2 LIQUIDITY On January 14, 2019, INVO Bioscience entered into a distribution agreement (the “Distribution Agreement”) with Ferring International Center S.A. (“Ferring”) which granted Ferring an exclusive licensing rights to sublicense the Company’s INVOcell together with the retention device for the U.S. market. Under the terms of the Distribution Agreement, Ferring was obligated to make an initial payment to the Company of $5,000,000 upon satisfaction of certain closing conditions. The Company received the initial $5 million cash payment upon the execution of the Ferring distribution agreement in January 2019. On November 12, 2020, the Company entered into an underwriting agreement (the “Underwriting Agreement”) with Roth Capital Partners, LLC, as representative of the several underwriters (the “Underwriters”), in connection with the Company’s public offering (the “Offering”) of 3,625,000 shares of the common stock, at a public offering price of $3.20 per share. The initial closing of the Offering for 3,625,000 shares of common stock took place on November 17, 2020. On November 18, 2020, the Underwriters exercised their option pursuant to the Underwriting Agreement to purchase an additional 528,750 shares of common stock (the “Option Shares”). The closing for the Option Shares took place on November 20, 2020 for which the Company received $1,522,800 in net proceeds after deducting underwriting discounts and commissions. With the exercise of the option to purchase the Option Shares, the total amount of shares of common Stock sold in the Offering was 4,153,750 shares with aggregate net proceeds received by the Company of $11,837,800 after deducting underwriting discounts and commissions and offering expenses. For the years ended December 31, 2020 and 2019, the Company had net losses of $8,347,316 and $2,167,544, respectively. The Company had working capital of $8,254,540 as of December 31, 2020, compared to $42,330 as of December 31, 2019. As of December 31, 2020, the Company’s stockholder’s equity was $5,743,106 compared to a deficiency of $3,713,595 as of December 31, 2019. Cash used in operation for 2020 was $4,775,148, compared to cash provided by operations of $1,370,513 for 2019. In connection with the preparation of its financial statements for the years ended December 31, 2020 and 2019, the Company’s management evaluated the Company’s ability to continue as a going concern in accordance with the ASU 2014-15, Presentation of Financial Statements Going Concern (Subtopic 205-40) As part of its evaluation, management assessed known events, trends, commitments, and uncertainties, which included the profitability of the Company and the cash flow generated by its operations, and the amount of capital recently and/or in the process of being raised. Working capital at December 31, 2020 improved by $8,212,210 from the previous year. As a result of the public offering on November 12, 2020, of 3,625,000 shares of common stock and an over-allotment of 528,750 shares of common stock on November 17, 2020 that resulted in net proceeds received of approximately $11.8 million, combined with the projected cash needs, management believes that it has completely mitigated the circumstance that led to a doubt with respect to the Company’s ability to continue as a going concern which existed at the time of the filing of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, and (ii) it has sufficient liquidity for at least the next 12 months.

INVENTORY

INVENTORY	12 Months Ended
	Dec. 31, 2020
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	NOTE 3 INVENTORY The components of inventory are: December 31, 2020 December 31, 2019 Raw materials $ 72,022 $ 44,333 Work in process 29,645 55,502 Finished goods 163,705 1,552 Total inventory $ 265,372 $ 101,387

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	12 Months Ended
	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	NOTE 4 PROPERTY AND EQUIPMENT The estimated useful lives and accumulated depreciation for furniture, equipment and software are as follows: Estimated Useful Life Manufacturing equipment 6 to 10 years Medical equipment 10 years Office equipment 3 to 7 years December 31, 2020 December 31, 2019 Manufacturing equipment- Molds $ 132,513 $ 132,513 Medical equipment 49,261 - Office equipment 2,689 2,689 Accumulated depreciation (52,256 ) (42,147 ) Property and equipment, net $ 132,206 $ 93,055 The Company recorded depreciation expense of $10,110 and $6,230 in 2020 and 2019, respectively.

PATENTS AND TRADEMARKS

PATENTS AND TRADEMARKS	12 Months Ended
	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets Disclosure [Text Block]	NOTE 5 PATENTS AND TRADEMARKS The Company capitalizes the initial expense related to establishing the patent by country and then amortizes the expense over the life of the patent, typically 20 years. It then expenses annual filing fees to maintain the patents. The Company regularly reviews the value of the patent in the marketplace in proportion to the expense it must spend to maintain the patent. The Company has recorded the following patent costs: December 31, 2020 December 31, 2019 Total Patents $ 77,722 $ 77,722 Accumulated Amortization (72,295 ) (70,488 ) Patent costs, net $ 5,427 $ 7,234 The Company recorded amortization expense of $1,807 and $4,558 in 2020 and 2019, respectively. Estimated amortization expense as of December 31, 2020 is as follows: Years ended December 31, 2021 $ 1,809 2022 1,809 2023 1,809 2024 - 2025 and thereafter - Total $ 5,427 As of December 31, 2020, and December 31, 2019, the Company recorded the following trademarks balances: December 31, 2020 December 31, 2019 Total trademarks $ 89,536 $ 49,867 Accumulated amortization - - Trademarks, net $ 89,536 $ 49,867 The trademarks have an indefinite life, so no amortization expense is calculated. Trademarks are periodically reviewed for impairment whenever circumstances and situations change such that there is an indication that the carrying amounts may not be recoverable. The Trademark assets were created in 2019 and no material adverse changes have occurred since their creation.

LEASES

LEASES	12 Months Ended
	Dec. 31, 2020
Disclosure Text Block [Abstract]
Lessor, Operating Leases [Text Block]	NOTE 6 LEASES The Company has an operating lease for our office, which have an initial term of 5 years with an option to renew for 3 additional years. There is no early termination clause included. The operating lease agreements does not contain any material restrictive covenants. Per FASB’s ASU 2016-02, Leases (Topic 842), effective January 1, 2019, the Company is required to report a right-of-use asset and corresponding liability to report the present value of the total least payments, with appropriate interest calculation. Per the terms of ASU 201-02, the Company can use its implicit interest rate, if known, or applicable federal rate otherwise. Since the Company’s implicit interest rate was not readily determinable, the Company utilized the applicable federal rate, which was 3.0% as of April 2019. ROU assets represent the Company’s right to use the underlying assets for the lease term and lease liabilities represent the net present value of the Company’s obligation to make payments arising from these leases. The lease liabilities are based on the present value of fixed lease payments over the lease term using the implicit lease interest rate or, when unknown, the Company's incremental borrowing rate on the lease commencement date. If the lease includes one or more options to extend the term of the lease, the renewal option is considered in the lease term if it is reasonably certain the Company will exercise the option(s). Operating lease expense is recognized on a straight-line basis over the term of the lease. As permitted by ASC 842, leases with an initial term of twelve months or less, or short-term leases, are not recorded on the accompanying consolidated balance sheet. The Company has lease agreements with lease and non-lease components, which are accounted for as a single lease component under the practical expedient provisions of the standard. The Company has lease agreements with terms less than one year. For the qualifying short-term leases, the Company elected the short-term lease recognition exemption in which the Company will not recognize ROU assets or lease liabilities, including the ROU assets or lease liabilities for existing short-term leases of those assets in upon adoption. Variable lease payments and short-term lease expenses were immaterial to the Company’s financial statements for the years ended December 31, 2020 and 2019. The Company’s lease agreements do not contain material restrictive covenants. The components of the lease assets and liabilities are as follows: Lease Component Balance Sheet Classification December 31, 2020 Assets ROU assets - operating lease Other assets $ 79,319 Total ROU assets $ 79,319 Liabilities Current operating lease liability Current liabilities $ 22,707 Long-term operating lease liability Other liabilities 58,634 Total lease liabilities $ 81,341 Rent expense is recognized on a straight-line basis over the life of the lease. Rent expense consists of the following: Year ended December 31, 2020 Operating lease costs $ 24,982 Total rent expense $ 24,982 Future minimum lease payments under non-cancellable leases were as follows: December 31, 2020 2021 $ 24,839 2022 25,585 2023 26,352 2024 8,870 2025 and beyond - Total future minimum lease payments $ 85,646 Less: Interest 4,305 Total operating lease liabilities $ 81,341 Current operating lease liability $ 22,707 Long-term operating lease liability 58,634 Total operating lease liabilities $ 81,341

CONVERTIBLE NOTES AND NOTES PAY

CONVERTIBLE NOTES AND NOTES PAYABLE	12 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
Long-term Debt [Text Block]	NOTE 7 CONVERTIBLE NOTES AND NOTES PAYABLE Notes Payable 2018 Convertible Notes Payable In April and May 2018, the Company issued convertible notes (the “2018 Convertible Notes”) payable to investors in the aggregate principal amount of $895,000. The 2018 Convertible Notes accrued interest at the rate of 9% per annum which was payable in stock. The 2018 Convertible Notes in an aggregate principal amount of $550,000, were due on January 30, 2020, and 2018 Convertible Notes with an aggregate principal amount of $345,000 were due on March 31, 2021. The notes were convertible into shares of common stock at a price of $6.40 per share, provided, that if the Company completes a subsequent equity financing, the holders of the 2018 Convertible Notes could elect to convert the notes in shares of the Company’s common stock at a price equal to 75% of the price paid per share in such subsequent equity financing. During the fourth quarter of 2018, three noteholders converted their notes with a value of $200,000 into 32,982 shares of common stock. During the twelve months ended December 31, 2019, two noteholders converted principal and accrued interest of $235,000 and $3,723, respectively, into a total of 37,301 shares of common stock. At inception of issuance, the Company calculated a beneficial conversion feature of the 2018 Convertible Notes in the form of a discount of $895,000; In May 2020, the remaining balance of $396,044, which included the principal balance of $420,000, accrued interest of $94,419, and the conversion discount of $118,375. As part of the extinguishment of the 2018 Convertible Notes, the Company issued 2020 Convertible Notes (as described below) to two remaining holders in the amount of $143,640. The remaining balance related to these notes was $116,693, which was comprised of a principal balance of $125,000, accrued interest of $23,318, net of the remaining discount of $31,625. In accordance with ASC 470, the extinguishment for these two holders was accounted for as a modification and no gain or loss was recorded. In May 2020, the remaining balance of $35,483, which included the principal balance of $40,000, accrued interest of $7,355, and a conversion discount of $11,872, was repaid. As of December 31, 2020, the balance of the 2018 Convertible Notes is $0. 2020 Convertible Notes Payable From May 15, 2020 through July 1, 2020, the Company entered into definitive securities purchase agreements (“Purchase Agreements”) with accredited investors for their purchase of (i) secured convertible notes issued by us in the aggregate original principal amount of $3,494,840 (the “Notes”), and (ii) Unit Purchase Options (“Purchase Options”) to purchase 303,623 units (each, a “Unit”), at an exercise price of $3.20 per Unit (subject to adjustments), with each Unit exercisable for (A) one share of the Company’s common stock and (B) a 5-year warrant (the “Warrants”) to purchase one share of our common stock at an exercise price of $3.20 (subject to adjustments) (the “Private Placement”). Each purchaser of a Note was issued a 5-year Purchase Option to purchase 0.086875 Units (as adjusted for the Reverse Splits (as defined below) for each dollar of Notes purchased. The Company received gross proceeds of approximately $3.5 million (of which $3,351,200 was received in cash and $143,640 resulted from cancellation of indebtedness). Tribal Capital Markets, LLC acted as placement agent (the “Placement Agent”) in the Private Placement. The Company paid the Placement Agent and certain selling agents a cash fee of 8% on a portion of the proceeds for an aggregate amount of $236,000. The Company also agreed to issue the Placement Agent and the selling agent 5-year warrants to purchase 6,750 shares of our common stock at an exercise price of $3.20. These warrants have the same terms and conditions as the Warrants issued in the Private Placement, except for the different exercise price. The Company received approximately $2,998,905 in net proceeds from the Private Placement, after deducting Placement Agent fees and selling agent fees payable to the Placement Agent and selling agent, respectively, and investor counsel in connection with the transaction. The Company used approximately $413,456, in proceeds to repay outstanding 9% promissory notes and the Company intends to use the remaining proceeds for working capital and general corporate purposes. Pursuant to that certain Form of Secured Convertible Note entered into in connection with the Purchase Agreement (the “Form of Note”), interest on such Notes accrues at a rates of ten percent (10%) per annum and is payable either in cash or in shares of the Company’s common stock at conversion price of $3.20 (following and subject to adjustment for stock splits, combinations or similar events and anti-dilution provisions, among other adjustments) on each of the six and twelve month anniversary of the issuance date and on the maturity dates of November 15, 2021, December 22, 2021 and December 30, 2021. All amounts of principal and interest due under the Notes are convertible at any time after the issuance date, in whole or in part (subject to rounding for fractional shares), at the option of the holders, into the Company’s common stock at a fixed conversion price of $3.20, which is subject to adjustment as described above. Upon any issuance by the Company of any of its equity securities, including common stock, for cash consideration, indebtedness or a combination thereof after the date hereof (a “Subsequent Equity Financing”), each holder of a Note will have the option to convert the outstanding principal and accrued but unpaid interest of its Note into the number of fully paid and non-assessable shares of common stock issued in the Subsequent Equity Financing (“Conversion Securities”) equal to the product of unpaid principal, together with the balance of unpaid and accrued interest and other amounts payable hereunder multiplied by 1.1, divided by the price per share paid by the investors for the Conversion Securities. A Note may not be converted, and shares of common stock may not be issued under the Notes if, after giving effect to the conversion or issuance, the holder together with its affiliates would beneficially own in excess of 9.99% of our outstanding ordinary shares. The Company may prepay the Notes at any time in whole or in part by paying an amount equal to 100% of the principal amount to be redeemed, together with accrued and unpaid interest plus a prepayment fee equal to one percent (1%) of the principal amount to be repaid. The Notes contain customary events of default including but not limited to: (i) failure to make payments when due; and (ii) bankruptcy or insolvency of the Company. If an event of default occurs, each holder may require the Company to redeem all or any portion of the Notes (including all accrued and unpaid interest thereon), in cash. The Notes are secured by the proceeds from the $3,000,000 milestone payment pursuant to Section 7.2(b) of the Distribution Agreement dated November 12, 2018 between the Obligor and Ferring International Center S.A., after such proceeds are actually received by the Company from Ferring, all pursuant to the terms of a Security Agreement entered into between the Company and the noteholders under the Purchase Agreements. Of the $3,494,840 in net proceeds received in the offering, $1,048,904 million was allocated to the unit purchase options issued to investors based on their relative fair value and $ 2,062,586 of beneficial conversion feature based on their relative fair value. This amount represented a discount on the debt and additional paid-in-capital at the date of issuance. In November 2020, $1,319,840 of principal elected to convert as part of the public underwritten offering. The remaining principal balances of the 2020 Convertible Notes were as follows: December 31, 2020 December 31, 2019 2020 Convertible Notes 1,700,000 - Accrued interest 24,373 - Less beneficial conversion feature discount (604,897 ) - Less options discount (224,051 ) - Less warrants discount (229,954 ) - Less issuance cost (129,408 ) - Total, net of discount $ 536,063 $ - Interest expense on the 2020 Convertible Note was $194,631 and $0 for the years ended December 31, 2020 and 2019, respectively. Amortization of options discount on the 2020 Convertible note was $300,365 and $0 for the years ended December 31, 2020 and 2019, respectively. Amortization of warrant discount on the 2020 Convertible Note was $301,228 and $0 for the years ended December 31, 2020 and 2019, respectively. Amortization of beneficial conversion feature on the 2020 Convertible Note was $1,670,135 and $0 for the years ended December 31, 2020 and 2019, respectively. Amortization of issuance costs on the 2020 Convertible Note was $222,508 and $0 for the years December 31, 2020 and 2019, respectively. On July 1, 2020, the Company received a loan in the principal amount of $157,620 relating to the U.S. Small Business Administration’s Paycheck Protection Program. The loan will mature 18 months from the date of funding is payable over 18 equal monthly installments, and bears interest at a rate of 1% per annum. The loan is forgivable up to 100% of the principal balance based upon satisfaction of certain criteria under the Paycheck Protection Program. The Company has applied for full forgiveness.

OTHER RELATED PARTY TRANSACTION

OTHER RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2020
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	NOTE 8 OTHER RELATED PARTY TRANSACTIONS On March 5, 2009, the Company entered into a related party transaction with Kathleen Karloff, the former Chief Executive Officer and a former Director of the Company. During the twelve months ended December 31, 2019, the Company paid the remaining balance due Ms. Karloff in the amount of $62,743 along with $55,000 of accrued interest. In April 2011, the Company issued a new short-term convertible note (“Q211 Note”) payable to James Bowdring in the amount of $50,000. The Note carries a 10% interest rate. The Company paid $25,000 of the Note in 2011 in cash. The Q211 Note is convertible into common stock of the Company at a conversion price of $0.96 per share, subject to adjustments. During the years ended December 31, 2020 and December 31, 2019, the Company accrued interest in the amount of $0 and $1,493 on the Q211 Note, respectively. In November 2011, the Company issued a new convertible note (“Q411 Note”) payable to James Bowdring in the amount of $10,000. The Q411 Note carries a 10% interest rate. The Q411 Note was converted into common stock of the Company at a conversion price of $0.32 per share, subject to adjustments. In addition, $0 and $597 of interest was accrued in the years ended December 31, 2020 and 2019, respectively. On August 7, 2019, the Company sent James Bowdring, a related party, a check in the amount of $65,197 as full payment of the foregoing promissory notes. On August 8, 2019, Mr. Bowdring’s legal counsel returned this check with a letter stating that the check did not properly account for the compound interest identified in such notes. In addition, the letter stated Mr. Bowdring’s desire to convert these promissory notes into shares of the Company’s common stock in lieu of any cash payment. The Company does not believe that Mr. Bowdring has the right to convert such notes upon receiving payment of such notes and intends to vigorously contest any conversion of these notes. In May 2018, James Bowdring and his children participated in the “2018 Convertible Notes” offerings in the aggregate principal amount of $40,000. The 2018 Convertible Notes accrue interest at the rate of 9% per annum which is paid in stock. These Notes are due on March 31, 2021. The notes are convertible into shares of common stock at a price of $6.40 per share, provided, that if the Company completes a subsequent equity financing, the holders of the 2018 Convertible Notes can elect to convert the notes in shares of our common stock at a price equal to 75% of the price paid per share in such subsequent equity financing. In addition, $1,380 and $3,599 of interest was accrued in the twelve months ended December 31, 2020 and 2019, respectively. Accounts payable and accrued liabilities balances include accrued directors fees, expenses reports for management and employees for expenses they paid for personally related to travel or normal business expenses. December 31, 2020 2019 Accounts payable and accrued liabilities $ 65,197 $ 41,842 In November 2020, Paulson Investment Company served as a co-managing underwriter for the Company’s underwritten public offering and received fee and commissions for such role in the amount of $271,440. Trent Davis, one of our directors is President of Paulson Investment Company. Mr. Davis did not receive any compensation related to the fees and commissions received by Paulson.

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	12 Months Ended
	Dec. 31, 2020
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	NOTE 9 STOCKHOLDERS EQUITY Reverse Stock Splits On December 16, 2019, the Company’s stockholders approved a reverse stock split at a ratio of between 1-for 5 and 1-for-25, with discretion for the exact ratio to be approved by the Company’s board of directors. On February 19, 2020, the Company’s board of directors approved a reverse stock split of the Company’s common stock at a ratio of 1-for-20. On May 21, 2020, the Company filed a certificate of change (with an effective date of May 26, 2020) with the Nevada Secretary of State pursuant to Nevada Revised Statutes 78.209 to effectuate a 1-for-20 reverse stock split of its outstanding common stock. The reverse split took effect at the open of business on May 26, 2020. On October 22, 2020 the Company’s board of directors approved a reverse stock split of the Company’s common stock at a ratio of 5-for-8 and also approved a proportionate decrease in the Company’s authorized common stock to 125,000,000 shares from 200,000,000. On November 5, 2020, the Company filed a certificate of change (with an effective date of November 9, 2020) with the Nevada Secretary of State pursuant to Nevada Revised Statutes 78.209 to effectuate a 5-for-8 reverse stock split of its outstanding common stock. As a result of the reverse stock split, 133 shares were issued in lieu of fractional shares. On November 6, 2020, the Company received notice from FINRA/OTC Corporate Actions that the reverse split would take effect at the open of business on November 9, 2020 and the reverse stock split took effect on that date. The consolidated financial statement presented reflect the reverse splits. Public offering On November 12, 2020, the Company entered into an underwriting agreement (the “Underwriting Agreement”) with Roth Capital Partners, LLC, as representative of the several underwriters (the “Underwriters”), in connection with the Company’s public offering (the “Offering”) of 3,625,000 shares of common stock, at a public offering price of $3.20 per share. The initial closing of the Offering for 3,625,000 shares of common stock took place on November 17, 2020. On November 18, 2020, the Underwriters exercised their option pursuant to the Underwriting Agreement to purchase an additional 528,750 shares of common stock (the “Option Shares”). The closing for the Option Shares took place on November 20, 2020 for which the Company received $1,522,800 in net proceeds after deducting underwriting discounts and commissions. With the exercise of the option to purchase the Option Shares, the total amount of shares of common stock sold in the Offering was 4,153,750 shares with aggregate net proceeds received by the Company of $11,837,800 after deducting underwriting discounts and commissions and offering expenses. During the year ended December 31, 2020 the Company incurred $1,816,948 of offering costs related to issuance of common stock. Year Ended December 31, 2020 In January 2020, the Company issued 31,250 shares of common stock under its 2019 Stock Incentive Plan with a fair value of $221,400 to an officer. In February 2020, the Company issued 3,125 shares of common stock under its 2019 Stock Incentive Plan with a fair value of $24,750 to an employee of which $20,626 was amortized in the twelve months ended December 31, 2020. In February 2020, the Company issued 3,098 shares of common stock under its 2019 Stock Incentive Plan with a fair value of $25,000 to a board member. In February 2020, the Company issued 3,098 shares of common stock under its 2019 Stock Incentive Plan with a fair value of $25,000 to a board member. In February 2020, the Company issued 1,875 shares of common stock under its 2019 Stock Incentive Plan with a fair value of $15,000 for services. In February 2020, pursuant to Section 4(a)(2) of the Securities Act of 1933 as amended (the “Securities Act”), the Company issued 1,563 shares of common stock with a fair value of $11,500 in consideration of consulting services rendered. The Company did not receive any proceeds from the issuance. In March 2020, pursuant to Section 4(a)(2) of the Securities Act, the Company issued 1,563 shares of common stock with a fair value of $11,500 in consideration of consulting services rendered. The Company did not receive any proceeds from the issuance. In May 2020, pursuant to Section 3(a)(9) of the Securities Act, the Company issued 24 shares of common stock as the result of the rounding on the reverse stock split. The Company did not receive any proceeds from the issuance. In May 2020, the Company issued 3,438 shares of common stock under its 2019 Stock Incentive Plan with a fair value of $25,930 to employees of which $19,287 was amortized in the twelve months ended December 31, 2020. In June 2020, pursuant to Section 4(a)(2) of the Securities Act, the Company issued 3,750 shares of common stock with a fair value of $22,800 in consideration of consulting services rendered. The Company did not receive any proceeds from the issuance. In August 2020, the Company issued 12,500 shares of restricted stock under its 2019 Stock Incentive Plan with a fair value of $72,200 to an employee of which $30,083 was amortized in the twelve months ended December 31, 2020. In August 2020, pursuant to Section 4(a)(2) of the Securities Act, the Company issued 3,750 shares of common stock with a fair value of $19,500 in consideration of consulting services rendered. The Company did not receive any proceeds from the issuance. In November 2020, pursuant to Section 4(a)(2) of the Securities Act, the Company issued 109 shares of common stock in consideration of consulting services rendered. The Company did not receive any proceeds from the issuance. In November 2020, the Company issued 4,153,750 shares of common stock for cash proceeds of $13,292,000. In November 2020, pursuant to Section 3(a)(9) of the Securities Act, the Company issued 453,699 shares of common stock with fair value of $1,451,824 are the result of the conversion of notes payables and accrued interest. No gain or loss was recorded on conversion, as the issuance of common stock was pursuant to the terms of a prior agreement. In November 2020, pursuant to Section 4(a)(2) of the Securities Act, the Company issued 22,250 shares of common stock with a fair value of $70,562 in consideration of consulting services rendered. The Company did not receive any proceeds from the issuance. In November 2020, the Company issued 5,793 shares of restricted stock under its 2019 Stock Incentive Plan with a fair value of $18,494 to directors of which $18,494 was amortized in the twelve months ended December 31, 2020. In December 2020, the Company issued 49,757 shares of restricted stock to directors under its 2019 Stock Incentive Plan, with a fair value of $152,700. Year Ended December 31, 2019 In January 2019, pursuant to Section 4(a)(2) of the Securities Act, the Company issued 1,875 shares of common stock with a fair value of $26,600 to service providers. In February 2019, pursuant to Section 4(a)(2) of the Securities Act, the Company issued 8,394 shares of common stock for conversion of notes payable and accrued interest in the amount of $53,723. In April 2019, pursuant to Section 4(a)(2) of the Securities Act, the Company issued 25,000 shares of common stock for conversion of notes payable in the amount of $160,000. In May 2019, pursuant to Section 4(a)(2) of the Securities Act, the Company issued 3,907 shares of common stock for conversion of notes payable in the amount of $25,000. In August 2019, pursuant to Section 4(a)(2) of the Securities Act, the Company issued 1,562 shares of common stock with a fair value of $15,000 to service providers. In November 2019, pursuant to Section 4(a)(2) of the Securities Act, the Company issued 625 shares of common stock with a fair value of $4,400 to service providers. In November 2019, pursuant to Section 4(a)(2) of the Securities Act, the Company issued 9,375 shares of common stock with a fair value of $93,750 pursuant a legal settlement signed on November 11, 2019.

EQUITY-BASED COMPENSATION

EQUITY-BASED COMPENSATION	12 Months Ended
	Dec. 31, 2020
Disclosure Text Block Supplement [Abstract]
Shareholders' Equity and Share-based Payments [Text Block]	NOTE 10 EQUITY-BASED COMPENSATION Equity Incentive Plans In October 2019, the Company adopted its 2019 Stock Incentive Plan (the "2019 Plan"). Under the 2019 Plan, the Company’s Board of Directors is authorized to grant both incentive and non-statutory stock options to purchase common stock and restricted stock awards to its employees, directors, and consultants. The 2019 Plan initially provided for the issuance of 500,000 shares. In January 2020, the number of available shares was increased to 793,093, pursuant to a provision in the 2019 Plan providing for an automatic annual increase equal to 6% of the total number of shares of Company common stock outstanding on December 31 of the preceding calendar year. Options generally have a life of 3 to 10 years and exercise price equal to or greater than the fair market value of the common stock as determined by the Company’s Board of Directors. Vesting for employees typically occurs over a three-year period or based on performance objective. The following table sets forth the activity of the options to purchase common stock under the 2019 Plan. The prices represent the closing price of our common stock on the OTC QB Venture Market until November 12, 2020 and the Nasdaq Capital Market on the respective dates. Options Outstanding Options Exercisable Number of Shares Price per Share Range Weighted Average Exercise Price Aggregate Intrinsic Value (1) Number of Shares Weighted Average Exercise Price Aggregate Intrinsic Value (1) Balance at December 31, 2018 - $ - $ - $ - - $ - $ - Granted 260,018 $ 8.16-9.25 $ 8.41 $ - $ - - Forfeited - $ - $ - $ - - $ - $ - Vested - $ - $ - $ - 11,256 $ 8.16 $ - Exercised - $ - $ - $ - - $ - $ - Balance at December 31, 2019 260,018 $ 8.16-9.25 $ 8.41 $ - 11,256 $ 8.16 $ - Granted 334,096 $ 3.19-8.32 $ 6.41 $ - $ - $ - $ - Forfeited - $ - $ - $ - - $ - $ - Vested - $ - $ - $ - 254,130 $ 5.01 $ - Exercised - $ - $ - $ - - $ - $ - Balance at December 31, 2020 594,114 $ 3.19-9.25 $ 7.28 $ - 265,386 $ 5.64 $ - (1) The intrinsic value of an option represents the amount by which the market value of the stock exceeds the exercise price of the option of in-the-money options only. The fair value of each option granted is estimated as of the grant date using the Black-Scholes option pricing model with the following assumptions: Years ended December 31, 2020 2019 Risk-free interest rate range 0.48%-1.65 % 1.6 % Expected life of option-years $5.00 -$5.77 2.9 Expected stock price volatility 110.8-208.3 % 117 % Expected dividend yield — % — % The risk-free interest rate is based on U.S. Treasury interest rates, the terms of which are consistent with the expected life of the stock options. Expected volatility is based upon the average historical volatility of our common stock over the period commensurate with the expected term of the related instrument. The expected life and estimated post-employment termination behavior is based upon historical experience of homogeneous groups, executives and non-executes, within the Company. The Company does not currently pay dividends on its common stock nor does it expect to in the foreseeable future. Options Outstanding Options Exercisable Range of Exercise Prices Options Outstanding Weighted Average Remaining Life in Years Weighted Average Exercise Price Options Exercisable Weighted Average Exercise Price of Options Exercisable Year ended December 31, 2018 $ - - - $ - - $ - Year ended December 31, 2019 $ 8.16-9.25 260,018 2.6 $ 8.40 11,256 $ 8.16 Year ended December 31, 2020 $ 3.19-9.25 594,114 3.5 $ 7.28 265,386 $ 5.64 Total Intrinsic Value of Options Exercised Total Fair Value of Options Vested Year ended December 31, 2018 $ - $ - Year ended December 31, 2019 $ - $ 69,787 Year ended December 31, 2020 $ - $ 1,495,744 For the years ended December 31, 2020, the weighted average grant date fair value of options granted was $6.94 per share. The Company estimates the fair value of options at the grant date using the Black-Scholes model. For all stock options granted through December 31, 2020, the weighted average remaining service period is 3.5 years. The Company recognized $1,141,042 in stock-based compensation expense, which is recorded in selling, general and administrative expenses on the consolidated statement of operations for the years ended December 31, 2019. Unamortized stock option expense at December 31, 2020 that will be amortized over the weighted-average remaining service period of 3.5 years totaled $1,832,069. Year December 31, 2020 On January 6, 2020, the Company granted one former employee a total of 2,500 options to purchase shares of the Company common at a price as of $7.04 per share. The Option Shares will vest when certain economic conditions are met by the Company and are exercisable until January 6, 2030. These economic conditions were met, and the options vested, on November 17, 2020. The total estimated value using the Black-Scholes Model, based on a volatility rate of 110.8%-128.0% and an option fair value of $5.94 was $14,851. On January 17, 2020, the Company granted one employee a total of 125,000 options to purchase shares of the Company common at a price as of $6.84 per share. The Option Shares will vest ratably over twenty-four (24) months and are exercisable until January 17, 2030. The total estimated value using the Black-Scholes Model, based on a volatility rate of 110.8%-128.0% and an option fair value of $5.94 was $742,542. On February 1, 2020, the Company granted one employee a total of 9,375 options to purchase shares of the Company common at a price as of $8.32 per share. The Option Shares will vest ratably over twenty-four (24) months and are exercisable until February 1, 2030. The total estimated value using the Black-Scholes Model, based on a volatility rate of 110.8%-128.0% and an option fair value of $6.56 was $61,487. On February 5, 2020, the Company granted five Board member a total of 15,490 options to purchase shares of the Company common at a price as of $8.07 per share. The Option Shares will vest 16.67% immediately, 83.33% will vest ratably over ten (10) months and are exercisable until December 5, 2030. The total estimated value using the Black-Scholes Model, based on a volatility rate of 110.8%-128.0% and an option fair value of $6.33 was $98,063. On March 23, 2020, the Company granted one employee a total of 12,500 options to purchase shares of the Company common at a price as of $8.32 per share. The Option Shares will vest ratably over thirty-six (36) months and are exercisable until March 23, 2030. The total estimated value using the Black-Scholes Model, based on a volatility rate of 110.8%-128.0% and an option fair value of $6.98 was $87,258. On April 6, 2020, the Company granted one employee a total of 938 options to purchase shares of the Company common at a price as of $8.32 per share. The Option Shares will vest ratably over thirty-six (36) months and are exercisable until March 10, 2030. The total estimated value using the Black-Scholes Model, based on a volatility rate of 117.8% and an option fair value of $5.77 was $5,412. On August 11, 2020, the Company granted one employee a total of 162,500 options to purchase shares of the Company common at a price as of $5.76 per share. The Option Shares will vest ratably over thirty-six (36) months and are exercisable until August 10, 2030. The total estimated value using the Black-Scholes Model, based on a volatility rate of 113.2% and an option fair value of $4.76 was $773,655. On November 27, 2020, the Company granted three Board members a total of 5,793 options to purchase shares of the Company common at a price as of $3.16 per share. The Option Shares will vest immediately and are exercisable until November 27, 2025. The total estimated value using the Black-Scholes Model, based on a volatility rate of 208.3% and an option fair value of $3.16 was $18,318. Twelve Months Ended December 31, 2019 On October 16, 2019, the Company granted one employee a total of 202,599 options to purchase shares of the Company common at a price as of $8.16 per share. The Option Shares will vest ratably over thirty-six (36) months and are exercisable until October 16, 2022. The total estimated value using the Black-Scholes Model, based on a volatility rate of 116.33% and an option fair value of $6.20 was $1,256,163. On October 29, 2019, the Company granted one former employee a total of 27,345 options to purchase shares of the Company common at a price as of $9.25 per share. The Option Shares will vest when certain economic conditions are met by the Company and are exercisable until October 25, 2029. These economic conditions were met, and the options vested, on November 17, 2020. The total estimated value using the Black-Scholes Model, based on a volatility rate of 119.98% and an option fair value of $7.70 was $210,564. On October 29, 2019, the Company granted one employee a total of 30,074 options to purchase shares of the Company common at a price as of $9.25 per share. The Option Shares will vest when certain economic conditions are met by the Company and are exercisable until October 25, 2029. These economic conditions were met, and the options vested, on November 17, 2020. The total estimated value using the Black-Scholes Model, based on a volatility rate of 119.98% and an option fair value of $7.70 was $231,579. Restricted Stock and Restricted Stock Units In 2020, we issued 70,302 of restricted stock, to certain employees. Shares issued to employees vest monthly over 1 year on the anniversary dates of their grant. In 2020 64,021 shares of restricted stock vested. The following table summarizes our aggregate restricted stock awards and restricted stock unit activity in 2020: Number of Unvested Shares Weighted Average Grant Date Fair Value Aggregate Grant Date Fair Value of Unvested Shares Balance at January 1, 2018 - $ - $ - Granted 12,500 $ 9.60 $ 120,000 Vested (2,083 ) $ 9.60 $ (20,000 ) Forfeitures (- ) $ - $ (- ) Balance at December 31, 2019 10,417 $ 9.60 $ 100,000 Granted 70,302 $ 6.23 $ 437,814 Vested (64,021 ) $ 7.18 $ (459,887 ) Forfeitures (- ) $ - $ (- ) Balance at December 31, 2020 16,698 $ 4.67 $ 77,927 The Company recognized $459,890 in stock-based compensation expense, which is recorded in selling, general and administrative expenses on the consolidated statement of operations for the years ended December 31, 2020, and the Company will recognize $77,927 over the remaining requisite service period.

STOCK OPTIONS AND WARRANTS

STOCK OPTIONS AND WARRANTS	12 Months Ended
	Dec. 31, 2020
Stock Options and Warrants [Abstract]
Stock Options and Warrants [Text Block]	NOTE 11 STOCK OPTIONS AND WARRANTS In connection with the issuance of the 2020 Convertible Notes, the Company also issued options to purchase 303,623 units at an exercise price of $3.20 per unit, with each unit consisting of one share of common stock, and a warrant to purchase one share of common stock at an exercise price of $3.20 per share. The units and warrants are exercisable for a period of five years from the date of issuance and are subject to a downward provision if the Company issues securities at a lower price. Warrant holders have a right to require the Company to pay cash in the event of a fundamental transaction. In accordance with ASC 815, the warrants and options issued in this period were determined to require equity treatment and $524,452 related to the options and $533,112 related to warrants was recorded in stockholders’ equity in the year ended December 31, 2020. In connection with the issuance of the 2020 Convertible Notes, the Company agreed to issue the placement agent and the selling agent five-year warrants to purchase 6,750 shares of the Company’s common stock at an exercise price of $3.20. In the year ended December 31, 2020, $47,293 was recorded in stockholders’ equity related to these warrants. A Monte Carlo model was used because the investor warrants and options contain fundamental transaction payouts and reset events that cannot be modeled with a Black Scholes model. The fair value of the options and warrants issued to the convertible debt holders is estimated as of the issue date using a Monte Carlo model with the following assumptions: Twelve Months ended December 31, 2020 2019 Risk-free interest rate range 0.38% - 0.39 % - % Stock Price $ 3.37 - 3.37 $ - Expected life of warrants and option (years) 4.47 - 4.62 - Expected stock price volatility 105.5% - 106.2 % - % Expected dividend yield 0 % - % The risk-free interest rate is based on U.S. Treasury interest rates, the terms of which are consistent with the expected life of the stock options and warrants. Expected volatility is based upon the historical volatility of the Company’s common stock over the period commensurate with the expected term of the related instrument. The options and warrants are valued assuming projected reset events adjusting the exercise price and a forced exercise upon a projected fundamental transaction by management. The options and warrants early exercise are modeled assuming registration after 180 days. The Company does not currently pay dividends on its common stock nor does it expect to in the foreseeable future.

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	NOTE 12 INCOME TAXES The provision for income taxes consists of the following for the year ended December 31, 2020 and 2019: December 31 2020 2019 Federal income taxes: Current - - Deferred (84 ) 349 Total federal income taxes (84 ) 349 State income taxes: Current 1,212 1824 Deferred 120 84 Total state income taxes 1,332 1908 Total income taxes $ 1,248 $ 2,257 The effective income tax rate is lower than the U.S. federal and state statutory rates primarily because of the valuation allowance and, to a lesser extent, permanent items. A reconciliation of the 2020 and 2019 federal statutory rate as compared to the effective income tax rate is as follows: December 31 2020 2019 Pre-Tax Book Income at Statutory Rate $ (1,688,606 ) 21.00 % $ (461,117 ) 21.00 % State Tax Expense, net 1,078 -0.01 % 1,524 -0.10 % Permanent Items 37,441 -0.47 % 26,430 -1.20 % True-Ups 6,790 -0.09 % Change in Federal Valuation Allowance 1,644,545 -20.45 % 435,420 -19.80 % Total Expense $ 1,248 -0.02 % $ 2,257 -0.10 % Deferred income taxes reflect the net effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax. Significant components of the deferred tax assets and liabilities as of December 31, 2020 and 2019, are as follows: December 31 2020 2019 Deferred tax assets: Accrued Compensation $ 127,829 $ 102,049 Amortization of Discount Notes Payable 93,017 99,635 Lease (ASC 842) 19,718 25,715 Charitable Contributions 127 - Stock Option Expense 28,212 - Restricted Stock Unit 10,665 - Deferred Revenue 865,747 1,112,807 Net Operating Losses 5,361,500 3,111,504 Gross deferred tax assets 6,506,815 4,451,710 Less: Valuation Allowance (6,408,401 ) (4,401,714 ) Net deferred tax asset: 98,414 49,996 Deferred tax liabilities: Fixed Assets (32,159 ) (24,281 ) ROU Lease (ASC 842) (19,228 ) (25,715 ) Trademark Amortization (1,529 ) (433 ) Convertible Note Interest Expense (42,111 ) - Note Issuance Cost (3,855 ) - Net deferred tax liability (98,882 ) (50,429 ) Net deferred tax liability $ (468 ) $ (433 ) The Company recorded a full valuation allowance against its net deferred tax asset at December 31, 2020 and 2019 totaling $6,408,401 and $4,401,714, respectively. A naked credit resulting from indefinite lived intangibles was valued at December 31, 2020 and 2019 totaling ($468) and ($433), respectively. As of December 31, 2020, the Company has federal net operating loss carryforwards totaling $21,819,421. Of that amount, $10,793,313 will expire, if not utilized, in various years beginning in 2028 and which are also subject to the limitations of IRC §382. The remaining carryforward amount of $11,026,108, has no expiration period and can be applied to 80% of taxable income per year in future periods. State net operating loss carryforwards total $16,774,460. Of that amount, $4,659,523 will begin to expire in 2033 and are subject to the limitations of IRC §382. The remaining $12,114,937 of state net operating loss carryforwards are similar to the federal net operating loss in that it has no expiration period and can be applied to 100% of state taxable income per year. IRC §382 of the Internal Revenue Code of 1986, as amended imposes an annual limit on the ability of a corporation that undergoes an “ownership change” to use its NOLs to reduce its tax liability. An “ownership change” is generally defined as any change in ownership of more than 50% of a corporation’s “stock” by its “5-percent shareholders” over a rolling three-year period based upon each of those shareholder’s lowest percentage of stock owned during such period. Such a change in ownership occurred in 2007. At this time, The Company does not believe this limitation, when combined with amounts allowable due to net unrecognized built in gains, will affect its ability to use any NOLs before they expire. The Company routinely inspect its income tax filings for current and previous positions that could be considered uncertain. If a position is deemed to carry a more-likely-than-not probability of notwithstanding challenge from a tax authority, the Company would record a liability for Uncertain Tax Positions (UTP) for the tax in question. As of December 31, 2020, and for all prior years, the Company does not and have not carried any UTP’s on the balance sheet. If a UTP was recorded, it is the Company’s policy to include interest and penalties on taxes as part of income tax expense. There are currently no income tax examinations being performed at the federal or state level and the Company is not aware of any possible future audits or examinations. The Company’s federal and state income tax returns from 2017 and forward remain open to examination by the corresponding taxing authorities under the statute of limitations, generally. However, due to the loss carryforwards established on historical tax filings, it is possible that the taxing authorities could examine tax years as far back as 2007 in order to determine if the net operating loss carryforward is appropriate.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	NOTE 13 COMMITMENTS AND CONTINGENCIES A) Litigation INVO Bioscience, Inc. v. James Bowdring On August 7, 2019, the Company sent James Bowdring, the brother of the Company’s then Chief Financial Officer, a check in the amount of $65,197 as full and final payment under those certain promissory notes dated April 8, 2011 and November 9, 2011. On August 8, 2019, Mr. Bowdring’s legal counsel returned the check. The basis for returning the check was a claim that the interest due under the Notes called for compounded interest and not per annum interest, this amount is recorded in Accounts Payable and Accrued Liabilities on the Consolidated Balance Sheet. In addition, the letter rejecting the tender of the payment in full check alleged Mr. Bowdring was considering a future intention to convert his Promissory Notes into shares of the Company’s common stock. Mr. Bowdring, through his counsel, indicated that such future intention to convert the Notes to common stock were contingent upon Mr. Bowdring addressing certain personal issues which were not disclosed by his counsel in the correspondence returning the checks. The Company does not believe that Mr. Bowdring has the right to seek conversion of the Notes once payment for the Notes has been tendered. In order to resolve the issue of the Company’s tender of payment in full versus Mr. Bowdring’s assertion that he can reject tender and seek conversion, the Company has filed an action in the Suffolk Superior Court in Boston on September 3, 2019 seeking Declaratory Judgment and Judgment for Breach of Contract. On September 30, 2019, Mr. Bowdring filed an answer and counterclaim under which he alleged breach of contract, fraud, promissory estoppel, unfair and deceptive practices and constructive trust. Mr. Bowdring is seeking receipt of all shares due under the adjusted conversion price. The 10% Senior Secured Convertible Promissory Notes were issued on April 8, 2011 and November 9, 2011, with maturity dates thirty days subsequent to the dates of issuance. Interest was calculated at 10% per annum, compounded based on a 360-day year. Investors had the option to convert any unpaid principal and accrued interest into shares of Company’s common stock original conversion prices of $0.96 and $0.32, respectively, subject to adjustments upon the Company’s issuances of stock at prices less than the original conversion prices during the 24-months after issuance of each note (i.e., currently $0.2100). The Company does not currently expect the above matter to have a material adverse effect upon either the Company’s results of operations, financial position, or cash flows. B) Employee Agreements On October 10, 2019, the Company entered into an agreement with our newly appointed CEO, Steve Shum. The Company agreed to pay Mr. Shum an annual salary of $260,000. In addition, Mr. Shum earned a bonus compensation of $75,000 bonus upon a successful up-listing to the Nasdaq exchange which was paid as of December 31, 2020. All other bonus amounts will be determined by the Board of Directors, at their sole discretion. In addition to his base salary and performance bonus, the Company granted Mr. Shum: (i) 400,000 shares of our common stock and (ii) a three-year option to purchase 6,483,171 shares of our common stock at an exercise price of $0.255 per share. These options will vest monthly over a 3-year period. On January 15, 2020, the Company entered into an employment agreement (the “Campbell Employment Agreement”) with Michael Campbell to continue serving as the Company’s Chief Operating Officer and Vice President of Business Development. The Campbell Employment Agreement provides for an annual base salary of $220,000, and a target annual incentive bonus of up to 50% of base salary if the Company achieves goals and objectives determined by the board of directors. In connection with the Campbell Employment Agreement, on January 17, 2020, the Company granted Mr. Campbell 31,250 shares of Company common stock, and an option to purchase 125,000 shares of Company common stock (the “Option”) at an exercise price of $6.84096 per share. One quarter of the Option vested upon grant, and the remainder vests in monthly increments over a period of two years from the date of grant. Mr. Campbell is also entitled to customary benefits, including health insurance and participation in employee benefit plans. The Campbell Employment Agreement provides that if Mr. Campbell terminates the Campbell Employment Agreement for “cause” (as defined in the Campbell Employment Agreement) or the Company terminates the Campbell Employment Agreement without “cause,” then he will continue to receive his base salary and certain insurance benefits for three months after termination. The Company may terminate the Campbell Employment Agreement without “cause” on 60 days’ notice. C) Consulting Agreements The Company has entered into a consulting agreement with Shine Management, Inc. through which it is receiving outsourced accounting and the support of its acting CFO, Debra Hoopes. Debra is the CFO and Chief Administrative Officer of Shine Management, Inc. and Management Services Company in Charlottesville, VA. (D) Major Customer Concentration Risk The Company has one major customer, Ferring, that accounted for approximately 98.3% and $1,019,286 of sales for the year ended December 31, 2020. The Company expects to maintain this relationship with the customer.

CONTRACTS WITH CUSTOMERS

CONTRACTS WITH CUSTOMERS	12 Months Ended
	Dec. 31, 2020
Revenue from Contract with Customer [Abstract]
Revenue from Contract with Customer [Text Block]	NOTE 14 CONTRACTS WITH CUSTOMERS The Company adopted ASC 606, Revenue from Contracts with Customers . Revenue Recognition The Company routinely enters into agreements with customers that include general commercial terms and conditions, notification requirements for price increases, shipping terms and in most cases prices for the products that it offers. However, these agreements do not obligate the Company to provide goods to the customer and there is no consideration promised to us at the onset of these arrangements. For customers without separate agreements, the Company has a standard list price established by geography and by currency for all products and our invoices contain standard terms and conditions that are applicable to those customers where a separate agreement is not controlling. The Company’s performance obligations are established when a customer submits a purchase order or notification (in writing, electronically or verbally) for goods, and it accept the order. The Company identifies performance obligations as the delivery of the requested product(s) in appropriate quantities and to the location specified in the customer’s e-mail/or purchase order. The Company generally recognizes revenue upon the satisfaction of these criteria when control of the product has been transferred to the customer at which time it has an unconditional right to receive payment. The Company’s prices are fixed and are not affected by contingent events that could impact the transaction price. The Company does not offer price concessions and does not accept payment that is less than the price stated when it accepted the purchase order, except in rare credit related circumstances. The Company does not have any material performance obligations where it is acting as an agent for another entity. Revenues for products, including: INVOcell®, INVO TM Retention System, and INVO Microscope Holding Block are typically recognized at the time the product is shipped, at which time the title passes to the customer, and there are no further performance obligations. Revenues from consignment are recognized when the medical device is shipped from the Consignor to the customer. In January 2019, the Company announced a U.S. license and distribution agreement with Ferring International Center S.A. (“Ferring”). The agreement calls for the issuance of an initial upfront payment of $5,000,000 which we received upon the signing of the agreement, ongoing product revenue, and then subsequent licensing fee payment of $3,000,000 that will provide us with a source of non-dilutive financing to execute our plan. Under the terms of the agreement the Company can pursue developing international markets and as well as partnering and opening INVO-only reproductive centers within the U.S. market. The initial upfront payment of $5,000,000 which the Company received upon the signing of the agreement is being recognized to income over the 7-year term. Under the terms of the Distribution Agreement, Ferring completed its obligation to make an initial payment to the Company of $5,000,000 upon completion of the required closing conditions, including executed agreements from all current manufacturers of the Licensed Product that upon a material supply default by the Company, Ferring can assume a direct purchase relationship with such manufacturers. Ferring is obligated to make a second payment to the Company of $3,000,000 provided that the Company is successful in obtaining a five (5) day label enhancement from the FDA for the current incubation period for the Licensed Product at least three (3) years prior to the expiration of the term of the license for the Licensed Product and provided further that Ferring has not previously exercised its right to terminate the Distribution Agreement for convenience. In addition, the Company entered into a separate Distribution Agreement. The Distribution Agreement has an initial term expiring on December 31, 2025 and at the end of the initial term it may be terminated by the Company if Ferring fails to generate specified minimum revenues to the Company from the sale of the Licensed Product during the final two years of the initial term. On March 2, 2021, the Company entered into Amendment No. 1 to the Distribution Agreement (the “Amendment”) with Ferring. Pursuant to the Amendment, Ferring agreed to purchase a 2,004 count of product for $501,000 in March 2021, at which point the minimum annual target for 2020 set forth in Section 2.4 of the Distribution Agreement will be deemed to be satisfied in full as a result of such purchase. The Amendment provides for added flexibility by increasing the number of INVO company-owned clinics initially allowable under the agreement and removing certain geographical requirements. The Ferring license was deemed to be a functional license that provide customers with a “right to access” to our intellectual property during the subscription period and, accordingly, revenue is recognized over a period of time, which is generally the subscription period. During the twelve months ended December 31, 2020, the Company recognized $714,286 related to the Ferring license agreement. As of December 31, 2020, and December 31, 2019, the Company had deferred revenues of $3,571,429 and $4,477,261, respectively. On September 20, 2019, the Company entered into an exclusive distribution agreement with Quality Medicines, Cosmetics & Medical Equipment Import for the territories of Sudan, Uganda and Ethiopia. This distribution agreement has a term of one year and may be extended by mutual agreement and is based on wholesale prices. Quality Medicines is required to register our product in each of these countries. On September 11, 2019, the Company entered into an exclusive distribution agreement with G-Systems Limited registered in Nigeria. In the territories of Nigeria. This distribution agreement has a term of one year and may be extended by mutual agreement and is based on wholesale prices. G-Systems is required to register our produce in Nigeria. On November 12, 2019, the Company announced that it had entered into exclusive distribution agreements with Biovate a Jordanian company for the territory of Jordan and Orcan Medical for the territory of Turkey. This agreement has a term of one year with extensions by mutual agreement. Safadi Drugstore is required to register our product in Jordan. On November 23, 2020, the Company entered into a Distribution Agreement with IDS Medical Systems (“Distributor”) to distribute the INVOcell system to Malaysia under which Distributor was appointed as the exclusive distributor in Malaysia. The Company can elect to terminate Distributor’s exclusivity upon its failure to meet certain purchase targets, in its sole discretion. The agreement is for a term of three years. The Company also granted Distributor an exclusive right to the INVO trademarks in Malaysia in connection with the sale of products in Malaysia. Sources of Revenue The Company has identified the following revenues disaggregated by revenue source: Domestic Product revenue Domestic Licensing fee For the twelve months ended December 31, 2020 and 2019 the source of revenue was derived from: December 31, 2020 December 31, 2019 Domestic Product revenue $ 323,000 $ 765,927 Domestic licensing fee 714,286 714,286 Total revenue $ 1,037,286 $ 1,480,213 Contract Balances The Company incurs agreement obligations on general customer purchase orders and e-mails that have been accepted but unfulfilled. Due to the short duration of time between order acceptance and delivery of the related product, the Company has determined that the balance related to these obligations is generally immaterial at any point in time. The Company monitors the value of orders accepted but unfulfilled at the close of each reporting period to determine if disclosure is appropriate. Warranty The Company’s general product warranties do not extend beyond an assurance that the product delivered will be consistent with stated specifications and do not include separate performance obligations. Significant Judgments in the Application of the Guidance in ASC 606 There are no significant judgments associated with the satisfaction of our performance obligations. The Company generally satisfy performance obligations upon delivery of the product to the customer. This is consistent with the time in which the customer obtains control of the products. Therefore, the value of unsatisfied performance obligations at the end of any reporting period is generally immaterial. The Company considers variable consideration in establishing the transaction price. Forms of variable consideration applicable to our arrangements include sales returns, rebates, volume-based bonuses, and prompt pay discounts. The Company uses historical information along with an analysis of the expected value to properly calculate and to consider the need to constrain estimates of variable consideration. Such amounts are included as a reduction to revenue from the sale of products in the periods in which the related revenue is recognized and adjusted in future periods as necessary. Commissions and Contract Costs The Company does not use or offer sales commissions of any type. The Company generally does not incur incremental charges associated with securing agreements with customers which would require capitalization and recovery over the life of the agreement. Practical Expedients The Company’s payment terms for sales direct to customers and distributors are substantially less than the one year collection period that falls within the practical expedient in determination of whether a significant financing component exists. Shipping and Handling Charges Fees charged to customers for shipping and handling of products are included as an offset to the costs for shipping and handling of products included as a component of cost of products.

INVESTMENT IN JOINT VENTURES

INVESTMENT IN JOINT VENTURES	12 Months Ended
	Dec. 31, 2020
Equity Method Investments and Joint Ventures [Abstract]
Equity Method Investments and Joint Ventures Disclosure [Text Block]	NOTE 15 INVESTMENT IN JOINT VENTURES The following table sets forth a list of the Company’s current joint venture arrangements. Subsidiary Name Country Percent (%) Ownership SNS MURNI INVO Bioscience Malaysia Sendirian Berhad Malaysia 50% Ginekalix INVO Bioscience LLC Skopje North Macedonia 50% Positib Fertility, S.A. de C.V Mexico 33% Medesole INVO Bioscience India India 50% The current joint venture arrangements are in the developmental stage and therefore only the initial startup costs are included in the financial statement for the year ended December 31, 2020. Malaysia JV Agreement On November 23, 2020, the Company entered into a separate joint venture agreement with SNS Murni SDN BHD (“SNS Murni”), a company incorporated in Malaysia, to establish an exclusive joint venture in Malaysia to (i) introduce, promote and market its technologies related to the INVOcell and INVO Procedure in dedicated government-owned fertility clinics in Malaysia, and (ii) establish INVO Clinics in Malaysia. The joint venture will be co-managed and owned 50% by each of INVO Bioscience and SNS Murni. For the year ended December 31, 2020 the Company has invested $7,348 in this joint venture. North Macedonia JV Agreement On November 23, 2020, the Company entered into a joint venture agreement with Ginekaliks Dooel (“Ginekaliks”), a limited liability company incorporated in the Republic of North Macedonia, to establish an exclusive joint venture to (i) commercialize, introduce, promote and market technologies related to the INVOcell and INVO Procedure in North Macedonia, (ii) establish a private healthcare institution to offer the INVO Procedure. The joint venture will be co-managed and owned 50% by each of INVO Bioscience and Ginekaliks. For the year ended December 31, 2020 the Company has invested $2,597 in this joint venture. Mexico JV Agreement Effective September 24, INVO Centers, LLC entered into a Pre-Incorporation and Shareholders Agreement with Francisco Arredondo, MD PLLC (“Arredondo”) and Security Health LLC, a Texas limited liability company (“Ramirez”, and together with INVO and Arredondo, the “Shareholders”) under which the Shareholders will commercialize the INVO Procedure and offer related medical treatments in Mexico. Each party will own one-third of the Mexican incorporated company, Positib Fertility, S.A. de C.V. (the “Mexico Company”). The Mexico Company will acquire the INVOcell product at cost plus any incurred shipping, customs and related fees. The Mexico Company will operate in Monterrey Nuevo Leon, Mexico and any other cities and places in Mexico as approved by the Mexico Company’s board of directors and Shareholders. In addition, the Shareholders agreed that the Mexico Company will be the Company’s exclusive distributor in Mexico. The Shareholders also agreed not to compete directly or indirectly with the Mexico Company in Mexico. For the year ended December 31, 2020 the Company has invested $51,670 in this joint venture. Medesole JV Agreement On January 13, 2020, the Company entered into a joint venture agreement (the “ Agreement Medesole Pursuant to the Agreement, the Company and Medesole will form a joint venture entity incorporated and registered in India, which will operate under the name Medesole INVO Bioscience India Private Limited (the “ JV The JV will be co-managed and owned 50% by each of INVO and Medesole, who will share equally in the expenditures, revenues and profits of the JV. The Agreement has a term of three years and may be terminated by either party on 180 days’ prior written notice. US Clinic JV Agreements As of December 31, 2020, the Company was in negotiations with several potential joint venture partners but had not yet entered into any definitive agreements for additional U.S. INVO Clinics. The Company has invested $30,340 in joint ventures the Company is currently exploring.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2020
Subsequent Events [Abstract]
Subsequent Events [Text Block]	NOTE 16 SUBSEQUENT EVENTS Alabama Joint Venture On March 10, 2021, the Company’s wholly owned subsidiary, INVO Centers, LLC (“INVO Centers”), entered into a limited liability company agreement (the “JV LLC Agreement”) with HRCFG, LLC (“HRCFG”) to form a joint venture for the purpose of commercializing INVOcell and the INVO Procedure at a dedicated fertility clinic in Birmingham, Alabama. The name of the joint venture LLC is HRCFG INVO, LLC (the “JV Company”). The responsibilities of HRCFG’s principals include providing clinical practice expertise, performing recruitment functions, providing all necessary training, and providing day-to-day management of the clinic. The responsibilities of INVO Centers will provide access to and will be the exclusive provider to the JV Company of the INVOcell and the INVO Procedure. INVO Centers will also perform all required in vitro fertilization, industry specific compliance and accreditation functions, and product documentation for product registration. The Company will also provide certain funding to the JV Company. In connection with the formation of the JV Company, the Company provided an initial $30,000 in funding, in exchange for a note issued by HRCFG, which will be repaid from the operating profit of the JV Company. Interest on the note accrues at a rate of 1.5%. In addition, the Company has agreed to issue 25,000 shares of our common stock to HRCFG (i) upon the Birmingham clinic opening for business, and (ii) upon each additional INVOcell clinic opened for business by the JV Company. In March 2021, the Company and HRCFG, as lessees, entered into a Lease Agreement with Trustmark National Bank, as lessor, for the lease of a 4,129 square foot facility in Birmingham, Alabama for the clinic associated with the JV LLC Agreement. The lease term will commence upon the earlier of June 1, 20201 or the opening of the clinic, and will be 86 months. The base rent per month will initially be $9,196.44 and will increase 2.25% each year. Amendment to Ferring Agreement On March 2, 2021, the Company entered into Amendment No. 1 to the Distribution Agreement (the “Amendment”) with Ferring. Pursuant to the Amendment, Ferring agreed to purchase a 2,004 count of product for $501,000 in March 2021, at which point the minimum annual target for 2020 set forth in Section 2.4 of the Distribution Agreement will be deemed to be satisfied in full as a result of such purchase. The Amendment provides for added flexibility by increasing the number of INVO company-owned clinics initially allowable under the agreement and removing certain geographical requirements. Equity Issuances In March 2021, three noteholders converted $1,237,624 of principal and accrued interest to 386,758 shares of common stock. In March 2021, the Company issued 77,444 shares of our common stock and 77,444 issued warrants upon exercise of outstanding unit purchase options for which it received $247,821 in proceeds. In March 2021, the Company issued 39,094 shares of our common stock upon exercise of outstanding warrants for which it received $125,104 in proceeds. In March 2021, the Company issued 85,568 shares of its common stock upon exercise of outstanding unit purchase options. The unit purchase options were exercised to purchase 131,114 shares and were exercised in full on a cashless basis and accordingly 45,546 shares were withheld at the market price of $9.20 per share less the exercise price of $3.20 per share to fund the exercise price. In March 2021, the Company issued 131,114 warrants upon the exercise in full of 131,114 unit purchase options. The Company did not receive any proceeds upon exercise. In March 2021, the Company issued 90,748 shares of our common stock upon exercise of outstanding warrants. The warrants were exercised to purchase 139,056 shares and were exercised in full on a cashless basis and accordingly 48,308 shares were withheld by the Company at the market price of $9.20 per share less the exercise price of $3.20 per share to fund the exercise price. In January 2021, the Company issued 58,500 shares of our common stock with a fair value of $179,490 in consideration of consulting services rendered. In February 2021, the Company issued 5,000 shares of our common stock with a fair value of $15,250 in consideration of consulting services rendered. In March 2021, the Company issued 8,000 shares of our common stock with a fair value of $26,640 in consideration of consulting services rendered. In January 2021, the Company issued 30,000 shares of our common stock under the 2019 Stock Incentive Plan with a fair value of $90,300 to five (5) employees.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation (Share Exchange and Corporate Structure) The accompanying consolidated financial statements present on a consolidated basis the accounts of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. Medesole JV Agreement On January 16, 2020, the Company announced a joint venture agreement for the Indian market. Under terms of the agreement, INVO and our partner, Medesole Healthcare and Trading Pvt Ltd (“Medesole”), will each own 50% of the joint venture. The Company will provide the device, training and general technology support to the joint venture, while Medesole will be responsible for the operations of INVO clinics in India. Both partners will equally invest in start-up and capital expenditures and share in the revenue and profits of the joint venture. The business model allows INVO to benefit not only from the sale of the device, but from the delivery of the entire solution. The current joint venture arrangements are in the developmental stage and therefore only the initial startup costs are included in the financial statement for the year ended December 31, 2020. Mexico JV Agreement Effective September 24, 2020, INVO Centers, LLC, entered into a Pre-Incorporation and Shareholders Agreement with Francisco Arredondo, MD PLLC (“Arredondo”) and Security Health LLC, a Texas limited liability company (“Ramirez”, and together with INVO and Arredondo, the “Shareholders”) under which the Shareholders will commercialize the INVO Procedure and offer related medical treatments in Mexico. Each party will own one-third of the Mexican incorporated company, Positib Fertility, S.A. de C.V. (the “Mexico Company”). The Mexico Company will acquire the INVOcell product at cost plus any incurred shipping, customs and related fees. The Mexico Company will operate in Monterrey Nuevo Leon, Mexico and any other cities and places in Mexico as approved by the Mexico Company’s board of directors and Shareholders. In addition, the Shareholders agreed that the Mexico Company will be the Company’s exclusive distributor in Mexico. The Shareholders also agreed not to compete directly or indirectly with the Mexico Company in Mexico. For the year ended December 31, 2020 the Company has invested $51,670 in this joint venture. This joint venture arrangements are in the developmental stage and therefore only the initial startup costs are included in the financial statement for the year ended December 31, 2020. North Macedonia JV Agreement On November 23, 2020, the Company entered into a joint venture agreement with Ginekaliks Dooel (“Ginekaliks”), a limited liability company incorporated in the Republic of North Macedonia, to establish an exclusive joint venture to (i) commercialize, introduce, promote and market technologies related to the INVOcell and INVO Procedure in North Macedonia, (ii) establish a private healthcare institution to offer the INVO Procedure. The joint venture will be co-managed and owned 50% by each of INVO and Ginekaliks. For the year ended December 31, 2020 the Company has invested $2,597 in this joint venture. This joint venture arrangements are in the developmental stage and therefore only the initial startup costs are included in the financial statement for the year ended December 31, 2020. Malaysia JV Agreement On November 23, 2020, the Company entered into a separate joint venture agreement with SNS Murni SDN BHD (“SNS Murni”), a company incorporated in Malaysia, to establish an exclusive joint venture in Malaysia to (i) introduce, promote and market our technologies related to the INVOcell and INVO Procedure in dedicated government-owned fertility clinics in Malaysia, and (ii) establish INVO Clinics in Malaysia. The joint venture will be co-managed and owned 50% by each of INVO Bioscience and SNS Murni. For the year ended December 31, 2020 the Company has invested $7,348 in this joint venture. This joint venture arrangements are in the developmental stage and therefore only the initial startup costs are included in the financial statement for the year ended December 31, 2020.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents For financial statement presentation purposes, the Company considers time deposits, certificates of deposit and all highly liquid investments with original maturities of three months or less to be cash and cash equivalents. At times, cash and cash equivalents balances exceed amounts insured by the Federal Deposit Insurance Corporation.
Inventory, Policy [Policy Text Block]	Inventory Inventories consist of raw materials, work in process and finished products and are stated at the lower of cost or market; using the first-in, first-out (FIFO) method as a cost flow convention.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment The Company records property and equipment at cost. Property and equipment is depreciated using the straight-line method over the estimated economic lives of the assets, which are from 3 to 10 years. The Company capitalizes the expenditures for major renewals and improvements that extend the useful lives of property and equipment. Expenditures for maintenance and repairs are charged to expense as incurred. The Company reviews the carrying value of long-lived assets for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets is measured by a comparison of its carrying amount to the undiscounted cash flows that the asset or asset group is expected to generate. If such assets are considered impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the property, if any, exceeds its fair market value.
Share-based Payment Arrangement [Policy Text Block]	Stock Based Compensation The Company accounts for stock-based compensation under the provisions of Accounting Standards Codification subtopic 718-10, Compensation (“ASC 718-10”). This statement requires the Company to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. That cost is recognized over the period in which the employee is required to provide service or based on performance goals in exchange for the award, which is usually the vesting period.
Earnings Per Share, Policy [Policy Text Block]	Loss Per Share Basic loss per share calculations are computed by dividing income (loss) available to common shareholders by the weighted-average number of common shares outstanding. Diluted earnings per share are computed similar to basic earnings per share except that the denominator is increased to include securities or other contracts to issue common stock that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. The Company’s diluted loss per share is the same as the basic loss per share for the years ended December 31, 2020 and 2019, as the inclusion of any potential shares would have had an anti-dilutive effect due to the Company generating a loss. Years Ended December 31, 2020 2019 Loss to common shareholders (Numerator) $ (8,347,316 ) $ (2,167,544 ) Basic and diluted weighted-average number of common shares outstanding (Denominator) 5,489,738 4,854,878 The Company has excluded the following dilutive securities from the calculation of fully diluted shares outstanding because the result would have been anti-dilutive: Years Ended December 31, 2020 2019 Effect of dilutive common stock equivalents: Options 594,114 260,018 Convertible notes and interest 536,302 85,324 Warrants 613,996 - Total 1,744,412 345,342
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments ASC 825-10-50, “Disclosures about Fair Value of Financial Instruments,” requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and borrowings, as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. Effective January 1, 2008, the Company adopted ASC 820-10, “Fair Value Measurements”, which provides a framework for measuring fair value under GAAP. ASC 820-10 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820-10 requires that valuation techniques maximize the use of observable inputs and minimize the use of unobservable inputs.
Income Tax, Policy [Policy Text Block]	Income Taxes The Company is subject to income taxes in the United States and its domestic tax liabilities are subject to the allocation of expenses in multiple state jurisdictions. The Company uses the asset and liability method to account for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The recoverability of deferred tax assets is evaluated by assessing the adequacy of future expected taxable income from all sources, including taxable income in prior carryback years, reversal of taxable temporary differences, forecasted operating earnings and available tax planning strategies. To the extent the Company does not consider it more-likely-than-not that a deferred tax asset will be recovered, a valuation allowance is established.
Segment Reporting, Policy [Policy Text Block]	Business Segments The Company operates in one segment and therefore segment information is not presented
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk Cash includes amounts deposited in financial institutions in excess of insurable Federal Deposit Insurance Corporation (“FDIC”) limits. As of December 31, 2020, the Company had cash balances in excess of FDIC limits.
Revenue [Policy Text Block]	Revenue Recognition The Company recognizes revenue on arrangements in accordance with ASC 606, Revenue from Contracts with Customers (“ASC 606”). The core principle of ASC 606 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services ASC 606 requires companies to assess their contracts to determine the timing and amount of revenue to recognize under the new revenue standard. The model has a five-step approach: 1. Identify the contract with the customer. 2. Identify the performance obligations in the contract. 3. Determine the total transaction price. 4. Allocate the total transaction price to each performance obligation in the contract. 5. Recognize as revenue when (or as) each performance obligation is satisfied. Revenues for products, including: INVOcell®, INVO TM Retention System, and INVO Microscope Holding Block are typically recognized at the time the product is shipped, at which time the title passes to the customer, and there are no further performance obligations. On November 12, 2018, we entered into a U.S. Distribution Agreement (the “Distribution Agreement”) with Ferring International Center S.A. (“Ferring”), which closed on January 14, 2019. At the closing, we received a $5,000,000 license payment upfront from Ferring. Pursuant to the Distribution Agreement, among other things, we granted Ferring an exclusive license in the United States market only, with rights to sublicense under patents related to our proprietary intravaginal culture device (INVOcell™), together with the retention device and any other applicable accessories (collectively, the “Licensed Product”) to market, promote, distribute and sell the Licensed Product with respect to all therapeutic, prophylactic and diagnostic uses of medical devices or pharmaceutical products involving reproductive technology (including infertility treatment) in humans (the “Field”). Ferring is responsible, at its own cost, for all commercialization activities for the Licensed Product in the U.S. market. We retained a limited exception to the exclusive license granted to Ferring allowing us, subject to certain restrictions, to establish up to five clinics that will commercialize INVO cycles in the U.S. This agreement was amended on March 2, 2021 to provide for added flexibility by increasing the number of INVO company-owned clinics initially allowable under the agreement and removing certain geographical requirements. Ferring is obligated to make a second payment to us of $3,000,000 upon procurement of a five (5) day label enhancement from the FDA for the current incubation period for the Licensed Product at least three (3) years prior to the expiration of the term of the license for the Licensed Product and provided further that Ferring has not previously exercised its right to terminate the Distribution Agreement for convenience. In addition, under the terms of a separate Supply Agreement, Ferring is obligated to pay us a specified supply price for each Licensed Product purchased by Ferring for distribution. The Distribution Agreement has an initial term expiring on December 31, 2025 and at the end of the initial term it may be terminated by us if Ferring fails to generate specified minimum revenues to us from the sale of the Licensed Product during the final two years of the initial term. Provided that no such termination occurs at the end of the initial term, thereafter the term of the Distribution Agreement shall automatically be renewed for successive three (3) years terms unless terminated by mutual consent. We retain all commercialization rights for the Licensed Product outside of the United States. The Ferring license was deemed to be a functional license that provide customers with a “right to access” to our intellectual property during the subscription period and accordingly, under ASC 606-10-55-60 revenue is recognized over a period of time, which is generally the subscription period. The initial upfront payment of $5,000,000 which was received upon the signing of the agreement is being recognized to income over the 7 year term.
Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]	Long- Lived Assets Long-lived assets and certain identifiable assets related to those assets are periodically reviewed for impairment whenever circumstances and situations change such that there is an indication that the carrying amounts may not be recoverable. If the non-discounted future cash flows of the enterprise are less than their carrying amount, their carrying amounts are reduced to the fair value and an impairment loss recognized. There was no impairment recorded during the years ended December 31, 2020 and 2019.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In February 2016, FASB issued ASU 2016-02, Leases (“ASU 2016-02”). The new standard establishes a right-of-use (“ROU”) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company adopted the standard effective January 1, 2019. The standard allows a number of optional practical expedients to use for transition. The Company chose the certain practical expedients allowed under the transition guidance which permitted the Company to not to reassess any existing or expired contracts to determine if they contain embedded leases, to not to reassess our lease classification on existing leases, to account for lease and non-lease components as a single lease component for equipment leases, and whether initial direct costs previously capitalized would qualify for capitalization under FASB ASC 842. The new standard also provides practical expedients and recognition exemptions for an entity's ongoing accounting policy elections. The Company has elected the short-term lease recognition for all leases that qualify, which means that we do not recognize a ROU asset and lease liability for any lease with a term of twelve months or less. The most significant impact of adopting the standard was the recognition of ROU assets and lease liabilities for operating leases on the Company's consolidated balance sheet but it did not have an impact on the Company's consolidated statements of operations or consolidated statements of cash flows. The Company did not have a cumulative effect on adoption prior to January 1, 2019. The Company adopted Accounting Standards Update No. 2016-02: Leases, or ASU 2016-02, effective January 1, 2019. ASC 842 superseded previously existing guidance on accounting for leases and generally requires all leases to be recognized in the statement of financial position. The adoption of ASC 842 had no impact on the Company’s consolidated statement of operations and consolidated statement of cash flows. The Company adopted ASC 842 on a modified retrospective approach at the effective date and, therefore, did not revise comparative period information or disclosure. In addition, the Company elected the package of practical expedients permitted under ASC 842. In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. This standard is intended to simplify the accounting and disclosure requirements for income taxes by eliminating various exceptions in accounting for income taxes as well as clarifying and amending existing guidance to improve consistency in application of ASC 740. The provisions of ASU 2019-12 are effective for fiscal years beginning after December 15, 2021, with early adoption permitted. The Company is currently evaluating the impact that ASU 2019-12 will have on its consolidated financial statements. In July 2017, FASB issued ASU 2017-11 (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception (“ASU 2017-11”). The new standard simplifies the accounting for certain financial instruments with down round features. Part I of ASU 2017-11 changes the classification analysis of certain equity-linked financial instruments, such as warrants and embedded conversion features, such that a down round feature is disregarded when assessing whether the instrument is indexed to an entity’s own stock under Subtopic 815-40, Contracts in Entity’s Own Equity. As a result, a down round feature, by itself, no longer requires an instrument to be re-measured at fair value through earnings each period, although all other aspects of the indexation guidance under Subtopic 815-40 continue to apply. Part II of ASU 2017-11 re-characterizes the indefinite deferral of certain provisions of Topic 480, Distinguishing Liabilities from Equity, (currently presented as pending content in the Codification) as a scope exception. No change in practice is expected as a result of these amendments. The new standard is effective for fiscal years beginning after December 15, 2018, early adoption is permitted. The amendments in Part II have no accounting impact and therefore do not have an associated effective date. The Company decided to early adopt this ASU 2017-11 and applied it to the convertible notes it issued during the quarter which are reflected in this Form 10-K. Management was not aware of any accounting issued, but not yet effective accounting standards, if currently adopted would have material effect on the consolidated financial statements.
Stockholders' Equity, Policy [Policy Text Block]	Reverse Stock Splits On May 26, 2020, the Company effected a 1-for-20 reverse stock split of its common stock. All shares, options and warrants throughout these consolidated financial statements have been retroactively restated to reflect the reverse split. On November 9, 2020, the Company effected a 5-for-8 reverse stock split of its common stock. All shares, options and warrants throughout these consolidated financial statements have been retroactively restated to reflect the reverse split.

ORGANIZATION AND SUMMARY OF S_2

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Basic loss per share calculations are computed by dividing income (loss) available to common shareholders by the weighted-average number of common shares outstanding. Diluted earnings per share are computed similar to basic earnings per share except that the denominator is increased to include securities or other contracts to issue common stock that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. The Company’s diluted loss per share is the same as the basic loss per share for the years ended December 31, 2020 and 2019, as the inclusion of any potential shares would have had an anti-dilutive effect due to the Company generating a loss. Years Ended December 31, 2020 2019 Loss to common shareholders (Numerator) $ (8,347,316 ) $ (2,167,544 ) Basic and diluted weighted-average number of common shares outstanding (Denominator) 5,489,738 4,854,878
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	The Company has excluded the following dilutive securities from the calculation of fully diluted shares outstanding because the result would have been anti-dilutive: Years Ended December 31, 2020 2019 Effect of dilutive common stock equivalents: Options 594,114 260,018 Convertible notes and interest 536,302 85,324 Warrants 613,996 - Total 1,744,412 345,342

INVENTORY (Tables)

INVENTORY (Tables)	12 Months Ended
	Dec. 31, 2020
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	The components of inventory are: December 31, 2020 December 31, 2019 Raw materials $ 72,022 $ 44,333 Work in process 29,645 55,502 Finished goods 163,705 1,552 Total inventory $ 265,372 $ 101,387

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2020
PROPERTY AND EQUIPMENT (Tables) [Line Items]
Property, Plant and Equipment [Table Text Block]	December 31, 2020 December 31, 2019 Manufacturing equipment- Molds $ 132,513 $ 132,513 Medical equipment 49,261 - Office equipment 2,689 2,689 Accumulated depreciation (52,256 ) (42,147 ) Property and equipment, net $ 132,206 $ 93,055
Estimated Useful Life [Member]
PROPERTY AND EQUIPMENT (Tables) [Line Items]
Property, Plant and Equipment [Table Text Block]	The estimated useful lives and accumulated depreciation for furniture, equipment and software are as follows: Estimated Useful Life Manufacturing equipment 6 to 10 years Medical equipment 10 years Office equipment 3 to 7 years

PATENTS AND TRADEMARKS (Tables)

PATENTS AND TRADEMARKS (Tables)	12 Months Ended
	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets [Table Text Block]	The Company has recorded the following patent costs: December 31, 2020 December 31, 2019 Total Patents $ 77,722 $ 77,722 Accumulated Amortization (72,295 ) (70,488 ) Patent costs, net $ 5,427 $ 7,234
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Estimated amortization expense as of December 31, 2020 is as follows: Years ended December 31, 2021 $ 1,809 2022 1,809 2023 1,809 2024 - 2025 and thereafter - Total $ 5,427
Schedule of Indefinite-Lived Intangible Assets [Table Text Block]	As of December 31, 2020, and December 31, 2019, the Company recorded the following trademarks balances: December 31, 2020 December 31, 2019 Total trademarks $ 89,536 $ 49,867 Accumulated amortization - - Trademarks, net $ 89,536 $ 49,867

LEASES (Tables)

LEASES (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure Text Block [Abstract]
Lessee, Operating Lease, Disclosure [Table Text Block]	The components of the lease assets and liabilities are as follows: Lease Component Balance Sheet Classification December 31, 2020 Assets ROU assets - operating lease Other assets $ 79,319 Total ROU assets $ 79,319 Liabilities Current operating lease liability Current liabilities $ 22,707 Long-term operating lease liability Other liabilities 58,634 Total lease liabilities $ 81,341
Lease, Cost [Table Text Block]	Rent expense is recognized on a straight-line basis over the life of the lease. Rent expense consists of the following: Year ended December 31, 2020 Operating lease costs $ 24,982 Total rent expense $ 24,982
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Future minimum lease payments under non-cancellable leases were as follows: December 31, 2020 2021 $ 24,839 2022 25,585 2023 26,352 2024 8,870 2025 and beyond - Total future minimum lease payments $ 85,646 Less: Interest 4,305 Total operating lease liabilities $ 81,341 Current operating lease liability $ 22,707 Long-term operating lease liability 58,634 Total operating lease liabilities $ 81,341

CONVERTIBLE NOTES AND NOTES P_2

CONVERTIBLE NOTES AND NOTES PAYABLE (Tables)	12 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
Convertible Debt [Table Text Block]	Principal balances of the 2020 Convertible Notes were as follows: December 31, 2020 December 31, 2019 2020 Convertible Notes 1,700,000 - Accrued interest 24,373 - Less beneficial conversion feature discount (604,897 ) - Less options discount (224,051 ) - Less warrants discount (229,954 ) - Less issuance cost (129,408 ) - Total, net of discount $ 536,063 $ -

OTHER RELATED PARTY TRANSACTI_2

OTHER RELATED PARTY TRANSACTIONS (Tables)	12 Months Ended
	Dec. 31, 2020
Related Party Transactions [Abstract]
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	Accounts payable and accrued liabilities balances include accrued directors fees, expenses reports for management and employees for expenses they paid for personally related to travel or normal business expenses. December 31, 2020 2019 Accounts payable and accrued liabilities $ 65,197 $ 41,842

EQUITY-BASED COMPENSATION (Tabl

EQUITY-BASED COMPENSATION (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure Text Block Supplement [Abstract]
Schedule of Stock Options Roll Forward [Table Text Block]	The following table sets forth the activity of the options to purchase common stock under the 2019 Plan. The prices represent the closing price of our common stock on the OTC QB Venture Market until November 12, 2020 and the Nasdaq Capital Market on the respective dates. Options Outstanding Options Exercisable Number of Shares Price per Share Range Weighted Average Exercise Price Aggregate Intrinsic Value (1) Number of Shares Weighted Average Exercise Price Aggregate Intrinsic Value (1) Balance at December 31, 2018 - $ - $ - $ - - $ - $ - Granted 260,018 $ 8.16-9.25 $ 8.41 $ - $ - - Forfeited - $ - $ - $ - - $ - $ - Vested - $ - $ - $ - 11,256 $ 8.16 $ - Exercised - $ - $ - $ - - $ - $ - Balance at December 31, 2019 260,018 $ 8.16-9.25 $ 8.41 $ - 11,256 $ 8.16 $ - Granted 334,096 $ 3.19-8.32 $ 6.41 $ - $ - $ - $ - Forfeited - $ - $ - $ - - $ - $ - Vested - $ - $ - $ - 254,130 $ 5.01 $ - Exercised - $ - $ - $ - - $ - $ - Balance at December 31, 2020 594,114 $ 3.19-9.25 $ 7.28 $ - 265,386 $ 5.64 $ - (1) The intrinsic value of an option represents the amount by which the market value of the stock exceeds the exercise price of the option of in-the-money options only.
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The fair value of each option granted is estimated as of the grant date using the Black-Scholes option pricing model with the following assumptions: Years ended December 31, 2020 2019 Risk-free interest rate range 0.48%-1.65 % 1.6 % Expected life of option-years $5.00 -$5.77 2.9 Expected stock price volatility 110.8-208.3 % 117 % Expected dividend yield — % — %
Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]	The risk-free interest rate is based on U.S. Treasury interest rates, the terms of which are consistent with the expected life of the stock options. Expected volatility is based upon the average historical volatility of our common stock over the period commensurate with the expected term of the related instrument. The expected life and estimated post-employment termination behavior is based upon historical experience of homogeneous groups, executives and non-executes, within the Company. The Company does not currently pay dividends on its common stock nor does it expect to in the foreseeable future. Options Outstanding Options Exercisable Range of Exercise Prices Options Outstanding Weighted Average Remaining Life in Years Weighted Average Exercise Price Options Exercisable Weighted Average Exercise Price of Options Exercisable Year ended December 31, 2018 $ - - - $ - - $ - Year ended December 31, 2019 $ 8.16-9.25 260,018 2.6 $ 8.40 11,256 $ 8.16 Year ended December 31, 2020 $ 3.19-9.25 594,114 3.5 $ 7.28 265,386 $ 5.64 Total Intrinsic Value of Options Exercised Total Fair Value of Options Vested Year ended December 31, 2018 $ - $ - Year ended December 31, 2019 $ - $ 69,787 Year ended December 31, 2020 $ - $ 1,495,744
Nonvested Restricted Stock Shares Activity [Table Text Block]	The following table summarizes our aggregate restricted stock awards and restricted stock unit activity in 2020: Number of Unvested Shares Weighted Average Grant Date Fair Value Aggregate Grant Date Fair Value of Unvested Shares Balance at January 1, 2018 - $ - $ - Granted 12,500 $ 9.60 $ 120,000 Vested (2,083 ) $ 9.60 $ (20,000 ) Forfeitures (- ) $ - $ (- ) Balance at December 31, 2019 10,417 $ 9.60 $ 100,000 Granted 70,302 $ 6.23 $ 437,814 Vested (64,021 ) $ 7.18 $ (459,887 ) Forfeitures (- ) $ - $ (- ) Balance at December 31, 2020 16,698 $ 4.67 $ 77,927

STOCK OPTIONS AND WARRANTS (Tab

STOCK OPTIONS AND WARRANTS (Tables)	12 Months Ended
	Dec. 31, 2020
Award Issued to Convertible Debt Holders [Member]
STOCK OPTIONS AND WARRANTS (Tables) [Line Items]
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	The fair value of the options and warrants issued to the convertible debt holders is estimated as of the issue date using a Monte Carlo model with the following assumptions: Twelve Months ended December 31, 2020 2019 Risk-free interest rate range 0.38% - 0.39 % - % Stock Price $ 3.37 - 3.37 $ - Expected life of warrants and option (years) 4.47 - 4.62 - Expected stock price volatility 105.5% - 106.2 % - % Expected dividend yield 0 % - %

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	The provision for income taxes consists of the following for the year ended December 31, 2020 and 2019: December 31 2020 2019 Federal income taxes: Current - - Deferred (84 ) 349 Total federal income taxes (84 ) 349 State income taxes: Current 1,212 1824 Deferred 120 84 Total state income taxes 1,332 1908 Total income taxes $ 1,248 $ 2,257
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	The effective income tax rate is lower than the U.S. federal and state statutory rates primarily because of the valuation allowance and, to a lesser extent, permanent items. A reconciliation of the 2020 and 2019 federal statutory rate as compared to the effective income tax rate is as follows: December 31 2020 2019 Pre-Tax Book Income at Statutory Rate $ (1,688,606 ) 21.00 % $ (461,117 ) 21.00 % State Tax Expense, net 1,078 -0.01 % 1,524 -0.10 % Permanent Items 37,441 -0.47 % 26,430 -1.20 % True-Ups 6,790 -0.09 % Change in Federal Valuation Allowance 1,644,545 -20.45 % 435,420 -19.80 % Total Expense $ 1,248 -0.02 % $ 2,257 -0.10 %
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	Deferred income taxes reflect the net effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax. Significant components of the deferred tax assets and liabilities as of December 31, 2020 and 2019, are as follows: December 31 2020 2019 Deferred tax assets: Accrued Compensation $ 127,829 $ 102,049 Amortization of Discount Notes Payable 93,017 99,635 Lease (ASC 842) 19,718 25,715 Charitable Contributions 127 - Stock Option Expense 28,212 - Restricted Stock Unit 10,665 - Deferred Revenue 865,747 1,112,807 Net Operating Losses 5,361,500 3,111,504 Gross deferred tax assets 6,506,815 4,451,710 Less: Valuation Allowance (6,408,401 ) (4,401,714 ) Net deferred tax asset: 98,414 49,996 Deferred tax liabilities: Fixed Assets (32,159 ) (24,281 ) ROU Lease (ASC 842) (19,228 ) (25,715 ) Trademark Amortization (1,529 ) (433 ) Convertible Note Interest Expense (42,111 ) - Note Issuance Cost (3,855 ) - Net deferred tax liability (98,882 ) (50,429 ) Net deferred tax liability $ (468 ) $ (433 )

CONTRACTS WITH CUSTOMERS (Table

CONTRACTS WITH CUSTOMERS (Tables)	12 Months Ended
	Dec. 31, 2020
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue [Table Text Block]	For the twelve months ended December 31, 2020 and 2019 the source of revenue was derived from: December 31, 2020 December 31, 2019 Domestic Product revenue $ 323,000 $ 765,927 Domestic licensing fee 714,286 714,286 Total revenue $ 1,037,286 $ 1,480,213

INVESTMENT IN JOINT VENTURES (T

INVESTMENT IN JOINT VENTURES (Tables)	12 Months Ended
	Dec. 31, 2020
Equity Method Investments and Joint Ventures [Abstract]
Investment [Table Text Block]	The following table sets forth a list of the Company’s current joint venture arrangements. Subsidiary Name Country Percent (%) Ownership SNS MURNI INVO Bioscience Malaysia Sendirian Berhad Malaysia 50% Ginekalix INVO Bioscience LLC Skopje North Macedonia 50% Positib Fertility, S.A. de C.V Mexico 33% Medesole INVO Bioscience India India 50%

ORGANIZATION AND SUMMARY OF S_3

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)	Nov. 23, 2020USD ($)	Nov. 09, 2020	Oct. 22, 2020	Sep. 24, 2020USD ($)	May 26, 2020	Jan. 16, 2020	Jan. 14, 2019USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Payments to Acquire Interest in Joint Venture								$ 98,084	$ 0
Number of Operating Segments								1
Proceeds from License Fees Received							$ 5,000,000		$ 5,000,000
Potential Licensing Fee							$ 3,000,000
Stockholders' Equity, Reverse Stock Split		5-for-8	5-for-8		1-for-20
Minimum [Member]
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Property, Plant and Equipment, Estimated Useful Lives								3
Maximum [Member]
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Property, Plant and Equipment, Estimated Useful Lives								10 years
Joint Venture, Medesol Healthcare and Trading Pvt Ltd [Member]
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Joint Venture, Ownership Percentage						50.00%
Joint Venture, Francisco Arredondo, MD PLLC [Member]
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Payments to Acquire Interest in Joint Venture				$ 51,670
Joint Venture, Ginekaliks Dooel [Member]
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Joint Venture, Ownership Percentage	50.00%
Payments to Acquire Interest in Joint Venture	$ 2,597
Joint Venture, SNS Murni SDN BHD [Member]
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Joint Venture, Ownership Percentage	50.00%
Payments to Acquire Interest in Joint Venture	$ 7,348

ORGANIZATION AND SUMMARY OF S_4

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Earnings Per Share, Basic and Diluted - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Schedule of Earnings Per Share, Basic and Diluted [Abstract]
Loss to common shareholders (Numerator)	$ (8,347,316)	$ (2,167,544)
Basic and diluted weighted-average number of common shares outstanding (Denominator)	5,489,738	4,854,878

ORGANIZATION AND SUMMARY OF S_5

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share - shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,744,412	345,342
Share-based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	594,114	260,018
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	536,302	85,324
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	613,996	0

LIQUIDITY (Details)

LIQUIDITY (Details) - USD ($)	Nov. 20, 2020	Nov. 18, 2020	Nov. 12, 2020	Jan. 14, 2019	Nov. 30, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Proceeds from License Fees Received				$ 5,000,000			$ 5,000,000
Offering, Shares (in Shares)			3,625,000
Shares Issued, Price Per Share (in Dollars per share)			$ 3.20
Stock Issued During Period, Shares, New Issues (in Shares)	4,153,750	528,750	3,625,000		4,153,750
Proceeds from Issuance or Sale of Equity	$ 11,837,800	$ 1,522,800	$ 11,800,000
Net Income (Loss) Attributable to Parent						$ (8,347,316)	(2,167,544)
Working Capital (Deficit)						(8,254,540)	42,330
Stockholders' Equity Attributable to Parent						5,743,106	(3,713,595)	$ (2,724,223)
Net Cash Provided by (Used in) Operating Activities						(4,775,148)	$ 1,370,513
Working Capital, Improvement						$ 8,212,210
Shares, over-allotment (in Shares)			528,750

INVENTORY (Details) - Schedule

INVENTORY (Details) - Schedule of Inventory, Current - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Schedule of Inventory, Current [Abstract]
Raw materials	$ 72,022	$ 44,333
Work in process	29,645	55,502
Finished goods	163,705	1,552
Total inventory	$ 265,372	$ 101,387

PROPERTY AND EQUIPMENT (Details

PROPERTY AND EQUIPMENT (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Depreciation	$ 10,110	$ 6,230

PROPERTY AND EQUIPMENT (Detai_2

PROPERTY AND EQUIPMENT (Details) - Property, Plant and Equipment, Estimated Useful Life	12 Months Ended
	Dec. 31, 2020
Machinery and Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	6 years
Machinery and Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	10 years
Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	10 years
Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	10 years
Office Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	3 years
Office Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	7 years

PROPERTY AND EQUIPMENT (Detai_3

PROPERTY AND EQUIPMENT (Details) - Property, Plant and Equipment - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
Accumulated depreciation	$ (52,256)	$ (42,147)
Property and equipment, net	132,206	93,055
Tools, Dies and Molds [Member]
Property, Plant and Equipment [Line Items]
Property, plant and Equipment, gross	132,513	132,513
Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and Equipment, gross	49,261	0
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and Equipment, gross	$ 2,689	$ 2,689

PATENTS AND TRADEMARKS (Details

PATENTS AND TRADEMARKS (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of Intangible Assets	$ 1,807	$ 4,558

PATENTS AND TRADEMARKS (Detai_2

PATENTS AND TRADEMARKS (Details) - Schedule of Finite-Lived Intangible Assets - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Schedule of Finite-Lived Intangible Assets [Abstract]
Total Patents	$ 77,722	$ 77,722
Accumulated Amortization	(72,295)	(70,488)
Patent costs, net	$ 5,427	$ 7,234

PATENTS AND TRADEMARKS (Detai_3

PATENTS AND TRADEMARKS (Details) - Schedule of Finite-Lived Intangible Assets, Future Amortization Expense - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Abstract]
2021	$ 1,809
2022	1,809
2023	1,809
2024	0
2025 and thereafter	0
Total	$ 5,427	$ 7,234

PATENTS AND TRADEMARKS (Detai_4

PATENTS AND TRADEMARKS (Details) - Schedule of Indefinite-Lived Intangible Assets - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Schedule of Indefinite-Lived Intangible Assets [Abstract]
Total Trademarks	$ 89,536	$ 49,867
Accumulated Amortization	0	0
Total Trademarks	$ 89,536	$ 49,867

LEASES (Details)

LEASES (Details)	12 Months Ended
	Dec. 31, 2020
Disclosure Text Block [Abstract]
Lessee, Operating Lease, Term of Contract	5 years
Lessee, Operating Lease, Renewal Term	3 years
Applicable Federal Rate	3.00%

LEASES (Details) - Lessee, Oper

LEASES (Details) - Lessee, Operating Lease, Disclosure - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Assets
ROU assets - operating lease	$ 79,319	$ 101,883
Total ROU assets	79,319
Liabilities
Current operating lease liability	22,707	21,365
Long-term operating lease liability	58,634	$ 81,494
Total lease liabilities	$ 81,341

LEASES (Details) - Lease, Cost

LEASES (Details) - Lease, Cost	12 Months Ended
	Dec. 31, 2020USD ($)
Lease, Cost [Abstract]
Operating lease costs	$ 24,982
Total rent expense	$ 24,982

LEASES (Details) - Lessee, Op_2

LEASES (Details) - Lessee, Operating Lease, Liability, Maturity - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Lessee, Operating Lease, Liability, Maturity [Abstract]
2021	$ 24,839
2022	25,585
2023	26,352
2024	8,870
2025 and beyond	0
Total future minimum lease payments	85,646
Less: Interest	4,305
Total operating lease liabilities	81,341
Current operating lease liability	22,707	$ 21,365
Long-term operating lease liability	$ 58,634	$ 81,494

CONVERTIBLE NOTES AND NOTES P_3

CONVERTIBLE NOTES AND NOTES PAYABLE (Details)	Nov. 12, 2020$ / shares	Jul. 31, 2020USD ($)	Jul. 01, 2020USD ($)$ / shares	May 31, 2020USD ($)	May 31, 2018USD ($)$ / shares	Nov. 30, 2020USD ($)shares	May 31, 2020USD ($)	Nov. 30, 2019USD ($)	May 31, 2019USD ($)shares	Apr. 30, 2019USD ($)shares	Feb. 28, 2019USD ($)shares	Jul. 01, 2020USD ($)$ / sharesshares	Dec. 31, 2018USD ($)shares	Dec. 31, 2020USD ($)$ / sharesshares	Dec. 31, 2019USD ($)shares	Dec. 31, 2011$ / shares
CONVERTIBLE NOTES AND NOTES PAYABLE (Details) [Line Items]
Debt Instrument, Face Amount			$ 157,620									$ 157,620
Debt Instrument, Interest Rate, Stated Percentage			1.00%									1.00%
Convertible Notes Payable														$ 536,063	$ 0
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares																$ 0.96
Debt Conversion, Original Debt, Amount						$ 1,451,824		$ 93,750	$ 25,000	$ 160,000	$ 53,723			1,451,824	238,723
Debt Conversion, Converted Instrument, Shares Issued (in Shares) | shares						453,699			3,907	25,000	8,394
Debt Instrument, Convertible, Beneficial Conversion Feature														2,062,586	0
Convertible Debt				$ 116,693			$ 116,693							1,700,000	0
Debt Instrument, Unamortized Discount				31,625			31,625
Unit, Exercise Price (in Dollars per share) | $ / shares	$ 3.20
Proceeds from Convertible Debt														157,620	0
Amortization of Debt Discount (Premium)														2,494,236	337,413
Debt Instrument, Term			18 months
Debt Instrument, Description			The loan is forgivable up to 100% of the principal balance based upon satisfaction of certain criteria under the Paycheck Protection Program
Equity Option [Member]
CONVERTIBLE NOTES AND NOTES PAYABLE (Details) [Line Items]
Debt Instrument, Unamortized Discount														224,051	0
Warrant [Member]
CONVERTIBLE NOTES AND NOTES PAYABLE (Details) [Line Items]
Debt Instrument, Unamortized Discount														229,954	0
Embedded Derivative Financial Instruments [Member]
CONVERTIBLE NOTES AND NOTES PAYABLE (Details) [Line Items]
Debt Instrument, Unamortized Discount														604,897	$ 0
Principal [Member]
CONVERTIBLE NOTES AND NOTES PAYABLE (Details) [Line Items]
Convertible Debt				125,000			125,000
Principal [Member] | Accrued Interest [Member]
CONVERTIBLE NOTES AND NOTES PAYABLE (Details) [Line Items]
Convertible Debt				23,318			23,318
The 2018 Convertible Notes [Member]
CONVERTIBLE NOTES AND NOTES PAYABLE (Details) [Line Items]
Debt Instrument, Face Amount				143,640	$ 895,000		143,640
Debt Instrument, Interest Rate, Stated Percentage					9.00%
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares					$ 6.40
Number of Note Holders													3
Debt Conversion, Original Debt, Amount													$ 200,000
Debt Conversion, Converted Instrument, Shares Issued (in Shares) | shares													32,982		37,301
Debt Instrument, Convertible, Beneficial Conversion Feature					$ 895,000
Repayments of Convertible Debt				35,483										396,044
Convertible Debt														0
The 2018 Convertible Notes [Member] | Principal [Member]
CONVERTIBLE NOTES AND NOTES PAYABLE (Details) [Line Items]
Number of Note Holders															2
Debt Conversion, Original Debt, Amount															$ 235,000
The 2018 Convertible Notes [Member] | Accrued Interest [Member]
CONVERTIBLE NOTES AND NOTES PAYABLE (Details) [Line Items]
Debt Conversion, Original Debt, Amount															3,723
The 2018 Convertible Notes [Member] | Principal [Member]
CONVERTIBLE NOTES AND NOTES PAYABLE (Details) [Line Items]
Repayments of Convertible Debt				40,000			420,000
The 2018 Convertible Notes [Member] | Accrued Interest [Member]
CONVERTIBLE NOTES AND NOTES PAYABLE (Details) [Line Items]
Repayments of Convertible Debt				7,355			94,419
The 2018 Convertible Notes [Member] | Conversion Discount [Member]
CONVERTIBLE NOTES AND NOTES PAYABLE (Details) [Line Items]
Repayments of Convertible Debt				$ 11,872			$ 118,375
The 2018 Convertible Notes, Due January 30, 2021 [Member]
CONVERTIBLE NOTES AND NOTES PAYABLE (Details) [Line Items]
Convertible Notes Payable					550,000
The 2018 Convertible Notes, Due March 31, 2021 [Member]
CONVERTIBLE NOTES AND NOTES PAYABLE (Details) [Line Items]
Convertible Notes Payable					$ 345,000
2020 Convertible Notes [Member]
CONVERTIBLE NOTES AND NOTES PAYABLE (Details) [Line Items]
Debt Instrument, Face Amount			$ 3,494,840									$ 3,494,840
Debt Instrument, Interest Rate, Stated Percentage			10.00%									10.00%
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares			$ 3.20									$ 3.20
Debt Conversion, Original Debt, Amount						$ 1,319,840
Debt Instrument, Convertible, Beneficial Conversion Feature														$ 2,062,586
Repayments of Convertible Debt		$ 413,456
Number of Units (in Shares) | shares												303,623		303,623
Unit, Description												each, a “Unit”), at an exercise price of $3.20 per Unit (subject to adjustments), with each Unit exercisable for (A) one share of the Company’s common stock and (B) a 5-year warrant (the “Warrants”) to purchase one share of our common stock at an exercise price of $3.20 (subject to adjustments) (the “Private Placement”). Each purchaser of a Note was issued a 5-year Purchase Option to purchase 0.086875 Units (as adjusted for the Reverse Splits (as defined below) for each dollar of Notes purchased.		each unit consisting of one share of common stock, and a warrant to purchase one share of common stock at an exercise price of $3.20 per share
Unit, Exercise Price (in Dollars per share) | $ / shares												$ 3.20		$ 3.20
Warrants and Rights Outstanding, Term			5 years									5 years		5 years
Proceeds from Convertible Debt												$ 3,351,200		$ 3,494,840
Debt Instrument, Decrease, Forgiveness												$ 143,640
Debt Instrument, Fee												cash fee of 8% on a portion of the proceeds
Debt Instrument, Fee Amount			$ 236,000									$ 236,000
Class of Warrant or Right, Granted (in Shares) | shares												6,750
Proceeds from Debt, Net of Issuance Costs												$ 2,998,905
Debt Instrument, Convertible, Terms of Conversion Feature												A Note may not be converted, and shares of common stock may not be issued under the Notes if, after giving effect to the conversion or issuance, the holder together with its affiliates would beneficially own in excess of 9.99% of our outstanding ordinary shares.
Debt Instrument, Payment Terms												The Company may prepay the Notes at any time in whole or in part by paying an amount equal to 100% of the principal amount to be redeemed, together with accrued and unpaid interest plus a prepayment fee equal to one percent (1%) of the principal amount to be repaid.
Debt Instrument, Collateral Amount			$ 3,000,000									$ 3,000,000
Interest Expense, Debt														194,631	0
Amortization of Debt Issuance Costs														222,508	0
2020 Convertible Notes [Member] | Equity Option [Member]
CONVERTIBLE NOTES AND NOTES PAYABLE (Details) [Line Items]
Amortization of Debt Discount (Premium)														300,365	0
2020 Convertible Notes [Member] | Warrant [Member]
CONVERTIBLE NOTES AND NOTES PAYABLE (Details) [Line Items]
Amortization of Debt Discount (Premium)														301,228	0
2020 Convertible Notes [Member] | Embedded Derivative Financial Instruments [Member]
CONVERTIBLE NOTES AND NOTES PAYABLE (Details) [Line Items]
Amortization of Debt Discount (Premium)														1,670,135	$ 0
Converted Account Payable to Promissory Note [Member]
CONVERTIBLE NOTES AND NOTES PAYABLE (Details) [Line Items]
Interest Expense, Debt														0
Options Held [Member] | 2020 Convertible Notes [Member]
CONVERTIBLE NOTES AND NOTES PAYABLE (Details) [Line Items]
Proceeds from Convertible Debt														$ 1,048,904

CONVERTIBLE NOTES AND NOTES P_4

CONVERTIBLE NOTES AND NOTES PAYABLE (Details) - Convertible Debt - USD ($)	Dec. 31, 2020	May 31, 2020	Dec. 31, 2019
CONVERTIBLE NOTES AND NOTES PAYABLE (Details) - Convertible Debt [Line Items]
2020 Convertible Notes	$ 1,700,000	$ 116,693	$ 0
Accrued interest	24,373		0
Less discount		$ (31,625)
Less issuance cost	(129,408)		0
Total, net of discount	536,063		0
Embedded Derivative Financial Instruments [Member]
CONVERTIBLE NOTES AND NOTES PAYABLE (Details) - Convertible Debt [Line Items]
Less discount	(604,897)		0
Equity Option [Member]
CONVERTIBLE NOTES AND NOTES PAYABLE (Details) - Convertible Debt [Line Items]
Less discount	(224,051)		0
Warrant [Member]
CONVERTIBLE NOTES AND NOTES PAYABLE (Details) - Convertible Debt [Line Items]
Less discount	$ (229,954)		$ 0

OTHER RELATED PARTY TRANSACTI_3

OTHER RELATED PARTY TRANSACTIONS (Details) - USD ($)	Aug. 07, 2019	Nov. 30, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2011	Jul. 01, 2020	May 31, 2020	May 31, 2018	Nov. 30, 2011	Apr. 30, 2011
OTHER RELATED PARTY TRANSACTIONS (Details) [Line Items]
Repayments of Related Party Debt			$ 40,000	$ 97,743
Debt Instrument, Face Amount						$ 157,620
Debt Instrument, Interest Rate, Stated Percentage						1.00%
Repayments of Notes Payable			770,000	131,722
Debt Instrument, Convertible, Conversion Price (in Dollars per share)					$ 0.96
The 2018 Convertible Notes [Member]
OTHER RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount							$ 143,640	$ 895,000
Debt Instrument, Interest Rate, Stated Percentage								9.00%
Debt Instrument, Convertible, Conversion Price (in Dollars per share)								$ 6.40
Chief Executive Officer [Member] | Principal [Member]
OTHER RELATED PARTY TRANSACTIONS (Details) [Line Items]
Repayments of Related Party Debt				62,743
Chief Executive Officer [Member] | Accrued Interest [Member]
OTHER RELATED PARTY TRANSACTIONS (Details) [Line Items]
Repayments of Related Party Debt				55,000
Immediate Family Member of Management or Principal Owner [Member]
OTHER RELATED PARTY TRANSACTIONS (Details) [Line Items]
Repayments of Related Party Debt	$ 65,197
Debt Instrument, Face Amount										$ 50,000
Debt Instrument, Interest Rate, Stated Percentage	10.00%									10.00%
Repayments of Notes Payable					$ 25,000
Debt Instrument, Convertible, Conversion Price (in Dollars per share)	$ 0.2100
Interest Expense, Related Party			0	1,493
Immediate Family Member of Management or Principal Owner [Member] | 2011 Notes [Member]
OTHER RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount									$ 10,000
Debt Instrument, Interest Rate, Stated Percentage									10.00%
Debt Instrument, Convertible, Conversion Price (in Dollars per share)									$ 0.32
Interest Expense, Related Party			0	597
Immediate Family Member of Management or Principal Owner [Member] | The 2018 Convertible Notes [Member]
OTHER RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount								$ 40,000
Debt Instrument, Interest Rate, Stated Percentage								9.00%
Debt Instrument, Convertible, Conversion Price (in Dollars per share)								$ 6.40
Interest Expense, Related Party			$ 1,380	$ 3,599
Director [Member]
OTHER RELATED PARTY TRANSACTIONS (Details) [Line Items]
Related Party Transaction, Amounts of Transaction		$ 271,440

OTHER RELATED PARTY TRANSACTI_4

OTHER RELATED PARTY TRANSACTIONS (Details) - Schedule of Accounts Payable and Accrued Liabilities - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Schedule of Accounts Payable and Accrued Liabilities [Abstract]
Accounts payable and accrued liabilities	$ 65,197	$ 41,842

STOCKHOLDERS' EQUITY (Details)

STOCKHOLDERS' EQUITY (Details) - USD ($)	Nov. 20, 2020	Nov. 18, 2020	Nov. 12, 2020	Nov. 09, 2020	Oct. 22, 2020	May 26, 2020	Dec. 31, 2020	Nov. 30, 2020	Aug. 31, 2020	Jun. 30, 2020	Mar. 31, 2020	Feb. 28, 2020	Jan. 31, 2020	Nov. 30, 2019	Aug. 31, 2019	May 31, 2019	Apr. 30, 2019	Feb. 28, 2019	Jan. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Oct. 21, 2020
STOCKHOLDERS' EQUITY (Details) [Line Items]
Stockholders' Equity, Reverse Stock Split				5-for-8	5-for-8	1-for-20
Common Stock, Shares Authorized					125,000,000		125,000,000													125,000,000	125,000,000	200,000,000
Stock Issued During Period, Shares, Reverse Stock Splits					133
Offering, Shares			3,625,000
Unit, Exercise Price (in Dollars per share)			$ 3.20
Stock Issued During Period, Shares, New Issues	4,153,750	528,750	3,625,000					4,153,750
Proceeds from Issuance or Sale of Equity (in Dollars)	$ 11,837,800	$ 1,522,800	$ 11,800,000
Payments of Stock Issuance Costs (in Dollars)																				$ 1,816,948
Stock Issued During Period, Shares, Issued for Services								22,250	3,750	3,750	1,563	1,563		625	1,562				1,875
Stock Issued During Period, Value, Issued for Services (in Dollars)								$ 70,562	$ 19,500	$ 22,800	$ 11,500	$ 11,500		$ 4,400	$ 15,000				$ 26,600	150,862	$ 46,600
Stockholders' Equity, Other Shares											24
Stock Issued During Period, Value, New Issues (in Dollars)								$ 13,292,000												11,475,052
Debt Conversion, Converted Instrument, Shares Issued								453,699								3,907	25,000	8,394
Debt Conversion, Original Debt, Amount (in Dollars)								$ 1,451,824						$ 93,750		$ 25,000	$ 160,000	$ 53,723		1,451,824	238,723
Restricted Stock, Shares Issued Net of Shares for Tax Withholdings								5,793
Restricted Stock, Value, Shares Issued Net of Tax Withholdings (in Dollars)								$ 18,494
APIC, Share-based Payment Arrangement, Increase for Cost Recognition (in Dollars)								$ 18,494
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture							49,757
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture (in Dollars)							$ 152,700													465,140	$ 17,750
Stock Issued During Period, Shares, Other														9,375
Consulting Services [Member]
STOCKHOLDERS' EQUITY (Details) [Line Items]
Stock Issued During Period, Shares, Issued for Services								109
2019 Plan [Member]
STOCKHOLDERS' EQUITY (Details) [Line Items]
Shares Issued, Shares, Share-based Payment Arrangement, before Forfeiture												3,125
Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture (in Dollars)												$ 24,750
Amortization of ESOP Award (in Dollars)																				20,626
Stock Issued During Period, Shares, Issued for Services												1,875
Stock Issued During Period, Value, Issued for Services (in Dollars)												$ 15,000
2019 Plan [Member] | Officer [Member]
STOCKHOLDERS' EQUITY (Details) [Line Items]
Shares Issued, Shares, Share-based Payment Arrangement, before Forfeiture													31,250
Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture (in Dollars)													$ 221,400
2019 Plan [Member] | Director [Member]
STOCKHOLDERS' EQUITY (Details) [Line Items]
Shares Issued, Shares, Share-based Payment Arrangement, before Forfeiture												3,098
Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture (in Dollars)												$ 25,000
2019 Plan [Member] | Employee [Member]
STOCKHOLDERS' EQUITY (Details) [Line Items]
Shares Issued, Shares, Share-based Payment Arrangement, before Forfeiture											3,438
Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture (in Dollars)											$ 25,930
Amortization of ESOP Award (in Dollars)																				19,287
Stock Issued During Period, Shares, Restricted Stock Award, Gross									12,500
Stock Issued During Period, Value, Restricted Stock Award, Gross (in Dollars)									$ 72,200
Restricted Stock [Member] | 2019 Plan [Member] | Employee [Member]
STOCKHOLDERS' EQUITY (Details) [Line Items]
Amortization of ESOP Award (in Dollars)																				$ 30,083

EQUITY-BASED COMPENSATION (Deta

EQUITY-BASED COMPENSATION (Details)	Nov. 27, 2020USD ($)$ / sharesshares	Oct. 16, 2020USD ($)$ / sharesshares	Aug. 11, 2020USD ($)$ / sharesshares	Apr. 06, 2020USD ($)$ / sharesshares	Mar. 23, 2020USD ($)$ / sharesshares	Feb. 05, 2020USD ($)$ / sharesshares	Feb. 01, 2020USD ($)$ / sharesshares	Jan. 17, 2020USD ($)$ / sharesshares	Jan. 06, 2020USD ($)$ / sharesshares	Jan. 01, 2020shares	Oct. 29, 2019USD ($)$ / sharesshares	Dec. 31, 2020USD ($)shares	Oct. 31, 2019shares	Dec. 31, 2020USD ($)$ / sharesshares	Dec. 31, 2019USD ($)$ / sharesshares	Dec. 31, 2018
EQUITY-BASED COMPENSATION (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Description										number of available shares was increased to 793,093, pursuant to a provision in the 2019 Plan providing for an automatic annual increase equal to 6% of the total number of shares of Company common stock outstanding on December 31 of the preceding calendar year
Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term														3 years 6 months	2 years 219 days	0 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share) | $ / shares	$ 3.16	$ 6.20	$ 4.76	$ 5.77	$ 6.98	$ 6.33	$ 6.56	$ 5.94	$ 5.94		$ 7.70
Share-based Payment Arrangement, Noncash Expense (in Dollars) | $														$ 1,140,989	$ 69,787
Number of Employees		1	1	1	1		1	1	1		1
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)	5,793	202,599	162,500	938	12,500	15,490	9,375	125,000	2,500		30,074
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share) | $ / shares	$ 3.16	$ 8.16	$ 5.76	$ 8.32	$ 8.32	$ 8.07	$ 8.32	$ 6.84	$ 7.04		$ 9.25			$ 6.41	$ 8.41
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	208.30%	116.33%	113.20%	117.80%							119.98%				117.00%
Fair Value of Option (in Dollars) | $	$ 18,318	$ 1,256,163	$ 773,655	$ 5,412	$ 87,258	$ 98,063	$ 61,487	$ 742,542	$ 14,851		$ 231,579
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		minus 36 months	minus 36 years	minus 36 months	36 months		minus 24 months	24 months
Number of Board Members	3					5
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights						vest 16.67% immediately, 83.33% will vest ratably over ten (10) months
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture (in Shares)												49,757
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in Shares)														64,021	2,083
Minimum [Member]
EQUITY-BASED COMPENSATION (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate					110.80%	110.80%	110.80%	110.80%	110.80%					110.80%
Maximum [Member]
EQUITY-BASED COMPENSATION (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate					128.00%	128.00%	128.00%	128.00%	128.00%					208.30%
Share-based Payment Arrangement, Option [Member]
EQUITY-BASED COMPENSATION (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share) | $ / shares											$ 7.70
Number of Employees											1
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)											27,345
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share) | $ / shares											$ 9.25
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate											119.98%
Fair Value of Option (in Dollars) | $											$ 210,564
Restricted Stock [Member]
EQUITY-BASED COMPENSATION (Details) [Line Items]
Share-based Payment Arrangement, Noncash Expense (in Dollars) | $														$ 459,890
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount (in Dollars) | $												$ 77,927		$ 77,927
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights														Shares issued to employees vest monthly over 1 year on the anniversary dates of their grant
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture (in Shares)														70,302
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in Shares)														64,021
2019 Plan [Member]
EQUITY-BASED COMPENSATION (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in Shares)													500,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in Shares)										793,093
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share) | $ / shares														$ 6.94
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term														3 years 6 months
Share-based Payment Arrangement, Noncash Expense (in Dollars) | $															$ 1,141,042
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition														3 years 6 months
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount (in Dollars) | $												$ 1,832,069		$ 1,832,069
2019 Plan [Member] | Minimum [Member]
EQUITY-BASED COMPENSATION (Details) [Line Items]
Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term													3 years
2019 Plan [Member] | Maximum [Member]
EQUITY-BASED COMPENSATION (Details) [Line Items]
Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term													10 years

EQUITY-BASED COMPENSATION (De_2

EQUITY-BASED COMPENSATION (Details) - Schedule of Stock Options Roll Forward - USD ($)		Nov. 27, 2020	Oct. 16, 2020	Aug. 11, 2020	Apr. 06, 2020	Mar. 23, 2020	Feb. 05, 2020	Feb. 01, 2020	Jan. 17, 2020	Jan. 06, 2020	Oct. 29, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
EQUITY-BASED COMPENSATION (Details) - Schedule of Stock Options Roll Forward [Line Items]
Balance, Options Outstanding, Number of Shares (in Shares)												260,018	0
Balance, Options Outstanding, Price per Share Range														$ 0
Balance, Options Outstanding, Weighted Average Exercise Price												$ 7.28	$ 8.41	$ 0
Balance, Options Outstanding, Aggregate Intrinsic Value (in Dollars)	[1]												$ 0	$ 0
Balance, Options Exercisable, Aggregate Intrinsic Value (in Dollars)	[1]												$ 0	$ 0
Balance, Options Exercisable, Number of Shares (in Shares)												11,256	0
Balance, Options Exercisable, Weighted Average Exercise Price												$ 5.64	$ 8.16	$ 0
Granted, Options Outstanding (in Shares)												334,096	260,018
Granted, Options Outstanding		$ 3.16	$ 8.16	$ 5.76	$ 8.32	$ 8.32	$ 8.07	$ 8.32	$ 6.84	$ 7.04	$ 9.25	$ 6.41	$ 8.41
Vested (in Shares)												254,130,000,000	11,256,000,000
Vested												$ 5.01	$ 8.16
Balance, Options Outstanding, Number of Shares (in Shares)												594,114	260,018
Balance, Options Exercisable, Number of Shares (in Shares)												265,386	11,256
Minimum [Member]
EQUITY-BASED COMPENSATION (Details) - Schedule of Stock Options Roll Forward [Line Items]
Balance, Options Outstanding, Price per Share Range												$ 3.19	$ 8.16
Granted, Options Outstanding												3.19	8.16
Maximum [Member]
EQUITY-BASED COMPENSATION (Details) - Schedule of Stock Options Roll Forward [Line Items]
Balance, Options Outstanding, Price per Share Range												9.25	9.25
Granted, Options Outstanding												$ 8.32	$ 9.25
[1]	The intrinsic value of an option represents the amount by which the market value of the stock exceeds the exercise price of the option of in-the-money options only.

EQUITY-BASED COMPENSATION (De_3

EQUITY-BASED COMPENSATION (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	Nov. 27, 2020	Oct. 16, 2020	Aug. 11, 2020	Apr. 06, 2020	Mar. 23, 2020	Feb. 05, 2020	Feb. 01, 2020	Jan. 17, 2020	Jan. 06, 2020	Oct. 29, 2019	Dec. 31, 2020	Dec. 31, 2019
EQUITY-BASED COMPENSATION (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]
Risk-free interest rate range												1.60%
Expected life of option-years												2 years 328 days
Expected stock price volatility	208.30%	116.33%	113.20%	117.80%						119.98%		117.00%
Expected dividend yield											0.00%	0.00%
Minimum [Member]
EQUITY-BASED COMPENSATION (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]
Risk-free interest rate range											0.48%
Expected life of option-years											5 years
Expected stock price volatility					110.80%	110.80%	110.80%	110.80%	110.80%		110.80%
Maximum [Member]
EQUITY-BASED COMPENSATION (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]
Risk-free interest rate range											1.65%
Expected life of option-years											5 years 281 days
Expected stock price volatility					128.00%	128.00%	128.00%	128.00%	128.00%		208.30%

EQUITY-BASED COMPENSATION (De_4

EQUITY-BASED COMPENSATION (Details) - Share-based Payment Arrangement, Option, Exercise Price Range - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices			$ 0
Options Outstanding (in Shares)	594,114	260,018	0	0
Weighted Average Remaining Life in Years	3 years 6 months	2 years 219 days	0 years
Weighted Average Exercise Price	$ 7.28	$ 8.40	$ 0
Options Exercisable (in Shares)	265,386	11,256	0
Weighted Average Exercise Price of Options Exercisable	$ 5.64	$ 8.16	$ 0
Total Intrinsic Value of Options Exercised (in Dollars)	$ 0	$ 0	$ 0
Total Fair Value of Options Vested (in Dollars)	$ 1,495,744	$ 69,787
Minimum [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices	$ 3.19	$ 8.16
Maximum [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices	$ 9.25	$ 9.25

EQUITY-BASED COMPENSATION (De_5

EQUITY-BASED COMPENSATION (Details) - Nonvested Restricted Stock Shares Activity - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Nonvested Restricted Stock Shares Activity [Abstract]
Balance, Number of Unvested Shares	10,417	0
Balance, Weighted Average Grant Date Fair Value	$ 9.60	$ 0
Balance, Aggregate Value of Unvested Shares	$ 100,000	$ 0
Granted, Number of Unvested Shares	70,302	12,500
Granted, Weighted Average Grant Date Fair Value	$ 6.23	$ 9.60
Granted, Aggregate Value of Unvested Shares	$ 437,814	$ 120,000
Vested, Number of Unvested Shares	(64,021)	(2,083)
Vested, Weighted Average Grant Date Fair Value	$ 7.18	$ 9.60
Vested, Aggregate Value of Unvested Shares	$ (459,887)	$ (20,000)
Forfeitures, Number of Unvested Shares	0	0
Forfeitures, Weighted Average Grant Date Fair Value	$ 0	$ 0
Forfeitures, Aggregate Value of Unvested Shares	$ 0	$ 0
Balance, Number of Unvested Shares	16,698	10,417
Balance, Weighted Average Grant Date Fair Value	$ 4.67	$ 9.60
Balance, Aggregate Value of Unvested Shares	$ 77,927	$ 100,000

STOCK OPTIONS AND WARRANTS (Det

STOCK OPTIONS AND WARRANTS (Details) - 2020 Convertible Notes [Member] - USD ($)	2 Months Ended	12 Months Ended
	Jul. 01, 2020	Dec. 31, 2020
STOCK OPTIONS AND WARRANTS (Details) [Line Items]
Number of Units (in Shares)	303,623	303,623
Unit, Exercise Price (in Dollars per share)	$ 3.20	$ 3.20
Unit, Description	each, a “Unit”), at an exercise price of $3.20 per Unit (subject to adjustments), with each Unit exercisable for (A) one share of the Company’s common stock and (B) a 5-year warrant (the “Warrants”) to purchase one share of our common stock at an exercise price of $3.20 (subject to adjustments) (the “Private Placement”). Each purchaser of a Note was issued a 5-year Purchase Option to purchase 0.086875 Units (as adjusted for the Reverse Splits (as defined below) for each dollar of Notes purchased.	each unit consisting of one share of common stock, and a warrant to purchase one share of common stock at an exercise price of $3.20 per share
Warrants and Rights Outstanding, Term	5 years	5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)		6,750
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)		$ 3.20
Adjustments to Additional Paid in Capital, Warrant Issued		$ 47,293
Share-based Payment Arrangement, Option [Member]
STOCK OPTIONS AND WARRANTS (Details) [Line Items]
Adjustments to Additional Paid in Capital, Other		524,452
Warrant [Member]
STOCK OPTIONS AND WARRANTS (Details) [Line Items]
Adjustments to Additional Paid in Capital, Other		$ 533,112

STOCK OPTIONS AND WARRANTS (D_2

STOCK OPTIONS AND WARRANTS (Details) - Fair Value Measurement Inputs and Valuation Techniques - Award Issued to Convertible Debt Holders [Member]	Dec. 31, 2020$ / shares	Dec. 31, 2019$ / shares
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Stock Price (in Dollars per share)		$ 0
Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Stock Price (in Dollars per share)	$ 3.37
Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Stock Price (in Dollars per share)	$ 3.37
Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Instrument, Measurement Input		0
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Instrument, Measurement Input	0.0038
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Instrument, Measurement Input	0.0039
Measurement Input, Expected Term [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Instrument, Measurement Input		0
Measurement Input, Expected Term [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Instrument, Measurement Input	4.47
Measurement Input, Expected Term [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Instrument, Measurement Input	4.62
Measurement Input, Price Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Instrument, Measurement Input		0
Measurement Input, Price Volatility [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Instrument, Measurement Input	1.055
Measurement Input, Price Volatility [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Instrument, Measurement Input	1.062
Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Instrument, Measurement Input	0	0

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
INCOME TAXES (Details) [Line Items]
Deferred Tax Assets, Valuation Allowance	$ 6,408,401	$ 4,401,714
Deferred Tax Assets, Goodwill and Intangible Assets	(468)	$ (433)
Operating Loss Carryforwards	21,819,421
Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration	10,793,313
Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration	11,026,108
State and Local Jurisdiction [Member]
INCOME TAXES (Details) [Line Items]
Operating Loss Carryforwards	16,774,460
Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration	4,659,523
Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration	$ 12,114,937

INCOME TAXES (Details) - Schedu

INCOME TAXES (Details) - Schedule of Components of Income Tax Expense (Benefit) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Federal income taxes:
Current	$ 0	$ 0
Deferred	(84)	349
Total federal income taxes	(84)	349
State income taxes:
Current	1,212	1,824
Deferred	120	84
Total state income taxes	1,332	1,908
Total income taxes	$ 1,248	$ 2,257

INCOME TAXES (Details) - Sche_2

INCOME TAXES (Details) - Schedule of Effective Income Tax Rate Reconciliation - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Schedule of Effective Income Tax Rate Reconciliation [Abstract]
Pre-tax book income	$ (1,688,606)	$ (461,117)
Pre-tax book income	21.00%	21.00%
State Tax Expense, net	$ 1,078	$ 1,524
State Tax Expense, net	(0.01%)	(0.10%)
Permanent Items	$ 37,441	$ 26,430
Permanent Items	(0.47%)	(1.20%)
True-Ups	$ 6,790
True-Ups	(0.09%)
Valuation Allowance	$ 1,644,545	$ 435,420
Valuation Allowance	(20.45%)	(19.80%)
Total Expense	$ 1,248	$ 2,257
Total Expense	(0.02%)	(0.10%)

INCOME TAXES (Details) - Sche_3

INCOME TAXES (Details) - Schedule of Deferred Tax Assets and Liabilities - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Deferred tax assets:
Accrued Compensation	$ 127,829	$ 102,049
Amortization of Discount Notes Payable	93,017	99,635
Lease (ASC 842)	19,718	25,715
Charitable Contributions	127	0
Stock Option Expense	28,212	0
Restricted Stock Unit	10,665	0
Deferred Revenue	865,747	1,112,807
Net Operating Losses	5,361,500	3,111,504
Gross deferred tax assets	6,506,815	4,451,710
Less: Valuation Allowance	(6,408,401)	(4,401,714)
Net deferred tax asset:	98,414	49,996
Fixed Assets	(32,159)	(24,281)
ROU Lease (ASC 842)	(19,228)	(25,715)
Trademark Amortization	(1,529)	(433)
Convertible Note Interest Expense	(42,111)	0
Note Issuance Cost	(3,855)	0
Net deferred tax liability	(98,882)	(50,429)
Net deferred tax liability	$ (468)	$ (433)

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details) - USD ($)

Nov. 27, 2020

Oct. 16, 2020

Aug. 11, 2020

Jul. 01, 2020

Apr. 06, 2020

Mar. 23, 2020

Feb. 05, 2020

Feb. 01, 2020

Jan. 17, 2020

Jan. 15, 2020

Jan. 06, 2020

Oct. 29, 2019

Oct. 10, 2019

Aug. 07, 2019

Dec. 31, 2020

Dec. 31, 2020

Dec. 31, 2019

Dec. 31, 2011

Apr. 30, 2011

COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Repayments of Related Party Debt

$ 40,000

$ 97,743

Debt Instrument, Term

18 months

Debt Instrument, Interest Rate, Stated Percentage

1.00%

Debt Instrument, Convertible, Conversion Price

$ 0.96

Salary and Wage, Officer, Excluding Cost of Good and Service Sold

$ 260,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

5,793

202,599

162,500

938

12,500

15,490

9,375

125,000

2,500

30,074

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 3.16

$ 8.16

$ 5.76

$ 8.32

$ 8.32

$ 8.07

$ 8.32

$ 6.84

$ 7.04

$ 9.25

$ 6.41

$ 8.41

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

minus 36 months

minus 36 years

minus 36 months

36 months

minus 24 months

24 months

Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture

49,757

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures

334,096

260,018

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights

vest 16.67% immediately, 83.33% will vest ratably over ten (10) months

Revenues

$ 1,037,286

$ 1,480,213

Chief Operating Officer [Member]

COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 6.84096

Employment Agreement, Annual Base Salary

$ 220,000

Employment Agreement, Bonus Description

target annual incentive bonus of up to 50% of base salary if the Company achieves goals and objectives determined by the board of directors

Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture

31,250

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures

125,000

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights

One quarter of the Option vested upon grant, and the remainder vests in monthly increments over a period of two years from the date of grant

Immediate Family Member of Management or Principal Owner [Member]

COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Repayments of Related Party Debt

$ 65,197

Debt Instrument, Term

30 days

Debt Instrument, Interest Rate, Stated Percentage

10.00%

10.00%

Debt Instrument, Convertible, Terms of Conversion Feature

Investors had the option to convert any unpaid principal and accrued interest into shares of Company’s common stock original conversion prices of $0.96 and $0.32, respectively, subject to adjustments upon the Company’s issuances of stock at prices less than the original conversion prices during the 24-months after issuance of each note (i.e., currently $0.2100)

Debt Instrument, Convertible, Conversion Price

$ 0.2100

Deferred Compensation Arrangement with Individual, Description

Mr. Shum earned a bonus compensation of $75,000 bonus upon a successful up-listing to the Nasdaq exchange which was paid as of December 31, 2020. All other bonus amounts will be determined by the Board of Directors, at their sole discretion.

Shares Issued, Shares, Share-based Payment Arrangement, Forfeited

400,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

6,483,171

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 0.255

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

3 years

Customer Concentration Risk [Member] | Revenue from Contract with Customer, Product and Service Benchmark [Member]

COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Concentration Risk, Percentage

98.30%

Revenues

$ 1,019,286

CONTRACTS WITH CUSTOMERS (Detai

CONTRACTS WITH CUSTOMERS (Details)	Mar. 02, 2021USD ($)	Nov. 23, 2020	Sep. 20, 2019	Sep. 19, 2019	Sep. 11, 2019	Jan. 14, 2019USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2020USD ($)
CONTRACTS WITH CUSTOMERS (Details) [Line Items]
Proceeds from License Fees Received						$ 5,000,000	$ 5,000,000
Potential Licensing Fee						$ 3,000,000
Contract With Customer, Term						7 years
Deferred Revenue							$ 4,477,261	$ 3,571,429
Sudan, Uganda, and Ethiopia [Member]
CONTRACTS WITH CUSTOMERS (Details) [Line Items]
Distribution Agreement, Term			1 year
NIGERIA
CONTRACTS WITH CUSTOMERS (Details) [Line Items]
Distribution Agreement, Term					1 year
JORDAN
CONTRACTS WITH CUSTOMERS (Details) [Line Items]
Distribution Agreement, Term				1 year
MALAYSIA
CONTRACTS WITH CUSTOMERS (Details) [Line Items]
Distribution Agreement, Term		3 years
Subsequent Event [Member]
CONTRACTS WITH CUSTOMERS (Details) [Line Items]
Proceeds from License Fees Received	$ 501,000
Number of Product Purchased	2,004

CONTRACTS WITH CUSTOMERS (Deta

CONTRACTS WITH CUSTOMERS (Details) - Disaggregation of Revenue - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Disaggregation of Revenue [Line Items]
Revenue	$ 1,037,286	$ 1,480,213
Domestic Physicians [Member]
Disaggregation of Revenue [Line Items]
Revenue	323,000	765,927
Domestic Licensing & Distribution Fee [Member]
Disaggregation of Revenue [Line Items]
Revenue	$ 714,286	$ 714,286

INVESTMENT IN JOINT VENTURES (D

INVESTMENT IN JOINT VENTURES (Details) - USD ($)	Nov. 23, 2020	Sep. 24, 2020	Dec. 31, 2020
Joint Venture, SNS Murni SDN BHD [Member]
INVESTMENT IN JOINT VENTURES (Details) [Line Items]
Joint Venture, Ownership Percentage	50.00%
Payments to Acquire Interest in Joint Venture	$ 7,348
Joint Venture, Ginekaliks Dooel [Member]
INVESTMENT IN JOINT VENTURES (Details) [Line Items]
Joint Venture, Ownership Percentage	50.00%
Payments to Acquire Interest in Joint Venture	$ 2,597
Joint Venture, Francisco Arredondo, MD PLLC [Member]
INVESTMENT IN JOINT VENTURES (Details) [Line Items]
Payments to Acquire Interest in Joint Venture		$ 51,670
US Clinc JV Agreeemnts [Member]
INVESTMENT IN JOINT VENTURES (Details) [Line Items]
Payments to Acquire Interest in Joint Venture			$ 30,340

INVESTMENT IN JOINT VENTURES _2

INVESTMENT IN JOINT VENTURES (Details) - Investment	12 Months Ended
	Dec. 31, 2020
Joint Venture, SNS Murni SDN BHD [Member]
INVESTMENT IN JOINT VENTURES (Details) - Investment [Line Items]
Country	Malaysia
Percent (%) Ownership	50.00%
Ginekalix INVO Bioscience LLC Skopje [Member]
INVESTMENT IN JOINT VENTURES (Details) - Investment [Line Items]
Country	North Macedonia
Percent (%) Ownership	50.00%
Positib Fertility, S.A. de C.V [Member]
INVESTMENT IN JOINT VENTURES (Details) - Investment [Line Items]
Country	Mexico
Percent (%) Ownership	33.00%
Medesole INVO Bioscience India [Member]
INVESTMENT IN JOINT VENTURES (Details) - Investment [Line Items]
Country	India
Percent (%) Ownership	50.00%

SUBSEQUENT EVENTS (Details)

SUBSEQUENT EVENTS (Details) - Subsequent Event [Member]	Mar. 10, 2021USD ($)shares	Mar. 02, 2021USD ($)	Mar. 31, 2021USD ($)ft²$ / sharesshares	Feb. 28, 2021USD ($)shares	Jan. 31, 2021USD ($)shares
SUBSEQUENT EVENTS (Details) [Line Items]
Payments to Acquire Interest in Joint Venture (in Dollars) | $	$ 30,000
Debt Instrument, Interest Rate, Stated Percentage	1.50%
Stock Issued During Period, Shares, Other	25,000		90,748
Area of Real Estate Property (in Square Feet) | ft²			4,129
Lessee, Operating Lease, Term of Contract			86 months
Operating Leases, Rent Expense, Minimum Rentals (in Dollars) | $	$ 9,196.44
Lease, Rent Increase, Percentage	2.25%
Number of Product Purchased		2,004
Proceeds from License Fees Received (in Dollars) | $		$ 501,000
Number of Note Holders			3
Debt Conversion, Original Debt, Amount (in Dollars) | $			$ 1,237,624
Debt Conversion, Converted Instrument, Shares Issued			386,758
Class of Warrant or Right, Granted			131,114
Stock Issued During Period, Shares, Conversion of Convertible Securities			139,056
Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation			48,308
Shares Issued, Price Per Share (in Dollars per share) | $ / shares			$ 9.20
Unit, Exercise Price (in Dollars per share) | $ / shares			$ 3.20
Units Exercised			131,114
Stock Issued During Period, Shares, Issued for Services			8,000	5,000	58,500
Stock Issued During Period, Value, Issued for Services (in Dollars) | $			$ 26,640	$ 15,250	$ 179,490
Shares Issued, Shares, Share-based Payment Arrangement, before Forfeiture					30,000
Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture (in Dollars) | $					$ 90,300
Number of Employees					5
Unit Purchase Exercise #2 [Member]
SUBSEQUENT EVENTS (Details) [Line Items]
Stock Issued During Period, Shares, New Issues			77,444
Class of Warrant or Right, Granted			77,444
Stock Issued During Period, Value, New Issues (in Dollars) | $			$ 247,821
Warrant Exercise [Member]
SUBSEQUENT EVENTS (Details) [Line Items]
Stock Issued During Period, Shares, Conversion of Convertible Securities			39,094
Proceeds from Warrant Exercises (in Dollars) | $			$ 125,104
Unit Purchase Exercise [Member]
SUBSEQUENT EVENTS (Details) [Line Items]
Stock Issued During Period, Shares, New Issues			131,114
Stock Issued During Period, Shares, Conversion of Convertible Securities			85,568
Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation			45,546
Shares Issued, Price Per Share (in Dollars per share) | $ / shares			$ 9.20
Unit, Exercise Price (in Dollars per share) | $ / shares			$ 3.20